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Abstract
Brucella spp. are a bacterium that cause brucellosis, a zoonotic disease, which is
commonly seen in cattle, sheep, goats, swine, and canines. Brucellosis is a problem worldwide,
although it is eradicated in some countries (Garin-Bastuji et al. 1998). The reason for designing
recombinant DNA (rDNA) vaccines opposed to utilizing the live-attenuated vaccines on the
market is that they cannot be given to pregnant animals without potentially causing abortion,
while an rDNA vaccine should be safe for pregnant animals since it does not contain viable
bacteria. Also, there are no serological tests that can accurately distinguish between an animal
vaccinated with the current vaccines available for brucellosis and an animal with an active
Brucella infection because the current vaccines are live-attenuated and interfere with diagnostics.
Recombinant DNA vaccines eliminate many safety concerns, which is why two rDNA vaccines
were constructed in the same way, except for the length of the immunogenic epitopes selected
from Brucella abortus. The epitopes from B. abortus that were chosen are present in the other
main species of Brucella because the main species of Brucella, such as B. abortus, B. melitensis,
and B. suis, are 99% identical at the DNA level. The epitopes range in length from 25 to 70
amino acids. Each vaccine contained a specific insert, with different lengths of epitopes and an
antibiotic resistance gene that was incorporated for selection of successfully transfected cells
during in vitro testing. After the vaccines were constructed, they were tested in vitro to determine
the vaccine’s ability to enter different cell types and show protein expression in a variety of cells.
The vaccines were tested in a caprine model to determine the vaccine’s ability to be successfully
expressed in mammalian cells in vivo. It was determined that no significant antibody
concentration was detected via the testing methods utilized.
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Literature Review
Brucellosis is a zoonotic disease caused by several species of the genus Brucella, which
are facultative intracellular bacteria. As of 2017, there have been 12 species of Brucella
identified (Al Dahouk et al. 2017). The six classical species include B. abortus, B. melitensis, B.
suis, B. ovis, B. canis, and B. neotomae, which are gram-negative coccobacillus. These classical
Brucella spp. can affect, but aren’t limited to cattle, sheep, goats, and canines (Hubálek et al.
2002) while some of the more recently discovered species have been isolated from marine
mammals, rodents, and amphibians (Whatmore et al. 2015). The six classical Brucella spp. are
highly related genetically (Godfroid et al. 2011) while other species of Brucella, including B.
microti, are related to the core Brucella spp., but represent a distinct basal lineage (Al Dahouk et
al. 2017). For example, the 6 main species are 99% identical to one another on the DNA level
with B. melitensis being the species used to determine homology.
Transmission of Brucella can occur in a variety of ways including contact with an
aborted placenta or fetus, fetal fluids and vaginal discharges from infected animals, milk, urine,
semen, and feces (Schwartz 2005). Common ways for infection to occur are through accidental
ingestion of these excretions, unpasteurized milk, or cheese made from an infected animal. It can
also be transmitted through mucous membranes, broken skin, and inhalation if the bacterium is
aerosolized. Brucella spp. can survive in dark humid environments for up to 6 months. The
bacterium can also survive for a month on the hairs of newborn animals born to an infected
mother. These qualities put other animals and people who live or work closely with livestock at
high risk of contracting brucellosis. Its ability to survive for long periods of time in dark and
humid places means that it can survive on fomites such as feeding or water troughs, which
increases the number of animals that are exposed to the bacteria (Schwartz 2005). Animals
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remain infectious after abortion or full-term parturition and can continue to shed the bacterium.
Brucella spp. are all zoonotic, but the degree of virulence varies. Regarding humans, B. abortus,
B. melitensis, and B. suis are the main species that can infect immunocompetent people while B.
canis can be problematic if the human in contact is immunocompromised in some way such as a
pregnant woman. Likewise, all Brucella spp. can be transmitted through aerosolization, but the
amount required for infection varies. Brucella melitensis requires a person to be exposed to 1-10
colony forming units (CFU), B. suis 100-1,000 CFU, B. abortus requires 1,000-10,000 CFU, B.
canis 106 CFU, and the other species require more significant amounts for infection (Teske et al.
2011).
One distinguishing feature of Brucella spp. is that they do not display obvious virulence
factors such as capsules, fimbriae, endotoxins, exoproteases or other exoenzymes, cytolysins,
resistance forms, antigenic variation, plasmids, or lysogenic phages. A genome analysis of three
of the Brucella spp. confirmed that there is an absence of most of the “classical” virulence
factors (Moreno and Moriyón 2002). The virulence of the Brucella spp. is mainly associated with
its lipopolysaccharide (LPS) phenotype; generally, the smooth LPS being virulent and the rough
ones not (Rittig et al. 2003). One of the main differences between smooth and rough LPS is that
smooth LPS has an O-chain while rough has a reduced, or is lacking, the O-side chain entirely.
Rough LPS can more readily attract and infect monocytes, but only smooth LPS can establish a
host niche within the cell and cause successful parasitism by replicating within the cell. The gene
manB/ppm is involved in LPS biosynthesis and is essential for virulence (Boschiroli et al. 2001).
This gene was identified by signature tagged mutagenesis (STM) and differential fluorescence
induction (DFI) as part of the bacterial envelope, specifically the O- antigen. Brucella abortus
and B. melitensis are only fully virulent in the smooth form and have reduced virulence when in
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the mutant rough form (Rittig et al. 2003). The LPS is thought to be important for the
extracellular survival of the bacterium and/or the intracellular survival within the host cell.
Genes specifically induced within the host are often essential virulence factors as well,
which is why rough LPS variants are still considered virulent. Brucella’s ability to survive and
create an intracellular environment in which to multiply within macrophages considerably
contributes to its virulence. The type IV secretion system plays an important role in intracellular
trafficking, which is essential for Brucella species. This system is homologous to the VirB
system found in Agrobacterium tumefaciens and it is responsible for virulence in both mice and
cultured cells. After invasion of a cell by Brucella spp. the phagosomes become acidified, which
acts as a signal to induce virulence factors (Boschiroli et al. 2001). Using DFI, it has been shown
that the virB promoter is specifically induced in macrophages and the acidification of the
phagosome is one of the signals. Through STM, the number of genes known to be involved in
the virulence of Brucella has increased but no new major virulence factors have been identified
(Boschiroli et al. 2001). Brucella virulence is an extremely efficient adaptation to shield itself
from immune recognition and to manipulate key aspects of the host cell physiology, such as the
ability to inhibit apoptosis (Godfroid et al. 2011). Key Outer Membrane Proteins (OMPs) play
important roles in inhibiting apoptosis and insuring the intracellular survival of the bacterium
(Zhang et al. 2016). Another in vivo adaptation is the ability to adjust the metabolism according
to the various nutrients involved in the infectious cycle. Quorum sensing (QS) is involved in the
regulation of virulence, mostly linked to the surface such as the type IV secretion system. It has
been suggested that it is involved either directly or indirectly in adjusting the Brucella
metabolism by slowing it down and preventing multiplication until the replicative compartment
is reached.
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While Brucella is found in a majority of countries and present in a variety of
mammalian species, most tests to determine its presence are non-definitive. To have a definitive
diagnosis, one needs to isolate the bacteria from blood, bone marrow, or another tissue (Al
Dahouk et al. 2003). Most often a diagnosis relies on the indirect proof of infection because most
bacteriological tests are time consuming and costly. Serology can be used to form a presumptive
diagnosis, but a variety of different serological tests must be applied to avoid false negative or
false positive results. Typically, Brucella Enzyme-linked Immunosorbent Assays (ELISA) are
used because these tests are the most sensitive and give the most specific results (Al Dahouk et
al. 2003). In goats, a polymerase chain reaction (PCR) was used to diagnose brucellosis and
compare the sensitivity against some common serological and bacterial techniques (LealKlevezas et al. 2000). The results showed that 86% of blood samples were positive using PCR,
while only 60% had a positive result when tested through serological methods. Sixty-four
percent of milk samples showed positive results through PCR testing but did not grow bacteria in
culture. This study showed that PCR testing has increased sensitivity in the detection of B.
abortus (Leal-Klevezas et al. 2000). However, false positive results have also been observed
with testing for Brucella since many tests, including PCR, cross react with the closely related
genera such as Ochrobactrum (Godfroid et al. 2011).
Through experimentally infected goats, it was discovered that B. abortus replicates in
the rough endoplasmic reticulum (RER) of trophoblasts. This unique localization of the bacteria
may play an important role in the replication of B. abortus in specific tissues and the
pathogenesis of bovine brucellosis (Meador and Deyoe 1989). A study done by Meador and
Deyoe suggests that because of the high numbers of Brucella resulting from intratrophoblastic
replication, the localization of B. abortus in the RER plays an important part in pathogenesis of
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Brucella-induced placentitis in infected females. Infected cattle showed a reduced amount or
lack of ribosomal lining of all membranes that were infected, which was likely due to infection
or placental detachment (Meador and Deyoe 1989). In the goats that were inoculated with B.
abortus there was trophoblast necrosis and ulceration of the membrane around the fetus. Because
of these results it is believed that B. abortus utilizes RER for synthesis or that it catabolizes the
trophoblast secretory proteins (Anderson et al. 1986).
Another problem with testing for Brucella spp. is the inability to distinguish between
vaccinated animals and animals that have an active infection. The main reason it is difficult or
impossible to distinguish between vaccinated and infected animals is that the vaccines on the
market are mainly live attenuated. These vaccines are produced by modifying the wild-type
bacteria in a laboratory which allows the vaccine organisms to replicate and produce immunity
but should not cause infection. However, since the whole bacterium is utilized in the vaccine it
does have the potential to cross react in testing. Brucella abortus vaccine strain 51 (RB51), a live
attenuated strain of B. abortus, is the vaccine that is most used to vaccinate cattle and it uses a
live attenuated strain of B. abortus. RB51 is a stable rough mutant derived from B. abortus
virulent Strain 2308 passed on media containing low concentrations of rifampicin, selecting for a
rough morphology (Dorneles et al. 2015 and Schurig et al. 1991). However, RB51 is also
pathogenic to humans, resistant to rifampicin, and not safe for use in pregnant cattle (Dorneles et
al. 2015). Likewise, the vaccine on the market for goats, Rev1, uses a live attenuated strain of B.
melitensis. This makes it difficult to determine whether an animal is currently infected or has
been previously vaccinated because differences between a virulent strain and a live-attenuated
strain are minimal. Since the vaccines are live attenuated, they can also cross the placenta of a
pregnant female and potentially harm the fetus, and infected animals cannot be slaughtered due
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to risk of human infection through infectious secretions. Use of a live virus can also be risky
because it has the potential to revert back to the wild-type form of the virulent strain and cause
infection (Liu 2003). The fact that RB51 and Rev1 cannot be administered to pregnant females
due to the high risk of abortion limiting its use and effectiveness in eradicating disease from
infected herds. The presence of Brucella bacteria in wild herds, such as elk and bison, creates
reservoirs of the bacteria and contributes to the inability to completely eradicate this disease.
As stated previously, the current live-attenuated strains raise safety concerns (Dorneles
et al. 2015). Heat-killed Brucella bacteria and protein subunit vaccines induce lower protection
and a Th2 biased response (Vitry et al. 2014 and Shedlock and Weiner 2000). The challenge of
developing safe brucellosis vaccines capable of stimulating multiple arms of the immune system
may be addressed by using multiple design strategies. DNA vaccination has been shown to
efficiently stimulate both Th1 and Th2 responses. The inclusion of multiple epitopes or epitope
dense regions from several antigens induces a broad immune response (Jain et al. 2014 and Afley
et al. 2015). The overall efficacy may be improved by targeting the immune response to
conserved and relevant antigens (Oseroff et al. 1998 and Holtappels et al. 2016). Therefore, a
multi-epitope DNA vaccine against B. abortus may provide increased safety, cross protection,
and efficacy compared to the current live-attenuated vaccines.
Brucellosis is characterized by retained placenta in females and to a lesser extent orchitis
and infection of the accessory sex glands in males. These symptoms are common among the
different species that can become infected by Brucella spp., but they can vary depending upon
the host. The primary host for B. abortus is cattle and the secondary host is goats, while for B.
melitensis the primary host is goats, and the secondary host is cattle. In these species the disease
is mainly characterized by abortions and placentitis in the female. Abortions are the main
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outcome in pregnant females due to the interactions between the intracellular brucellae, the
placenta, and the fetus, which is not well understood (Moreno and Moriyón 2002). Male dogs,
rams, and boars can show signs of testicular swelling, but the symptoms in males are not as
prevalent of an issue as the female symptoms. Swine are the primary host for B. suis and the
secondary hosts include cattle and dogs. Sows have similar symptoms as cows and does, but
boars can spread the bacteria in their semen during service (Olsen and Tatum 2017). The primary
host for B. ovis is sheep, for B. canis it is dogs, and the primary host for B. neotomae is the desert
woodrat. None of these three species have common secondary hosts associated with them.
Brucella ovis can cause occasional abortions, but the main effect is on the ram. Rams with B.
ovis show signs of reduced fertility, epididymitis, and orchitis. In canines, bitches have abortions
and reduced fertility, and male canines can show signs of spondylosis, as can boars (Hensel et al.
2018). Some strains of Brucella become less virulent when they infect the incorrect host.
Abortion is the main cause of concern from infection with Brucella bacterium in herd
animals. However, there are 500,000 new cases annually worldwide in humans with many more
cases going undiagnosed (Skalsky et al. 2008). In humans, the main symptoms are undulating
fever and flu-like myalgias and arthralgias. Chronic infections could lead to more serious
symptoms including peripheral arthritis, sacroiliitis, orchitis, endocarditis, and neurobrucellosis
(Smith 2018). In humans, the bacterium can infect any organ in the body. Although some are
very rare, it usually occurs in organs that are rich in elements of reticuloendothelial systems
(RES) which is expected because brucellae can survive and replicate in the mononuclear
phagocytes (monocytes and macrophages) of this area. Although different organs and organ
systems can be involved, symptoms are generally non-specific, and diagnoses made with
certainty usually relies upon isolating the bacterium from blood, bone marrow, or other tissues
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(Young 1995). To create an effective anti-Brucella drug there must be good penetration into
infected cells. In humans, antibiotics are used as a treatment for brucellosis including
doxycycline in combination with streptomycin, gentamicin or rifampicin, and tetracycline
compounds (Young 1995). A meta- analysis was performed by Skalsky and colleagues to
determine the most effective treatments for human brucellosis. The authors concluded in a metaanalysis that doxycycline in combination with rifampicin was the most effective combination of
treatments. Streptomycin and gentamicin were found to be interchangeable when given with
doxycycline. When treating with tetracycline, the tetracycline-streptomycin combination was far
superior to tetracycline-rifampicin especially in terms of preventing relapsing symptoms. All
studies concluded that treatment for 6 weeks or more were more effective at preventing relapses
than treatments lasting only 3-4 weeks (Skalsky et al. 2008).
Most developed countries are under the regime of “test and slaughter” when it comes to
animals diagnosed with the disease, as opposed to treating them. Many developing countries do
not test for Brucella prior to slaughter or at the slaughterhouse due to lack of animal health
infrastructure (Hull and Schumaker 2018). However, the “test and slaughter” method has helped
reduce the number of infected animals in developed countries.
Brucellosis can have a large impact on farm animals and their non-domesticated
counterparts, such as bison and elk. Brucella melitensis is mainly found in places such as
Mediterranean Europe, the Middle East, and many South American countries where humans and
livestock live in close contact with one another. Although it is considered eradicated or not
present in some countries, it is still thought to be a worldwide concern (Garin-Bastuji et al.
1998). Unlike B. melitensis, B. abortus, is present in the United States. B. abortus is found
throughout the world in cattle raising regions. It is considered eradicated in domesticated cattle
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in the United States but is present in wildlife. Though not an issue in the United States, B.
melitensis is a noteworthy threat to animals and humans outside of the U.S. and causes
significant economic impact, particularly in developing countries.
As stated earlier, the 6 main species of Brucella are 99% identical on the DNA level and
B. melitensis is the species that was used to determine homology among these species. Brucella
melitensis and B. abortus were shown to be morphologically and culturally indistinguishable but
are distinguishable biochemically. Hoyer and McCullough were the first to explore the Brucella
genome in depth through DNA-DNA hybridization experimentation (Hoyer and McCullough
1968). They established that B. melitensis, B. abortus, B. suis, and B. neotame had 100%
homology in their polypeptide sequences while B. ovis showed 94% homology with the other
species. Brucella canis was shown to have DNA homology with the 3 classical species: B.
melitensis, B. abortus, and B. suis. Through reciprocal DNA-DNA hybridization it was
established that the difference in B. ovis from the classical species was due to a missing 6% of
sequence from the common genome. Verger et al. examined the homology among the
polypeptide sequences of 51 strains of Brucella, which included representatives of all 6 species
and their respective biotypes. DNA from B. melitensis 16M was used to determine homology
among the 51 strains and Verger reported binding ratios from 84-100% (Verger et al. 1985). De
Ley et al. was the one to establish with certainty that there was genetic similarity among the 6
species of Brucella, and it was shown that there is little to no measurable difference among them
(De Ley et al. 1987). This was shown on a similarity map depicting data from DNA ribosomal
RNA hybridization (Nielsen 1990). Since there is such similarity among the genomic DNA of
the Brucella spp. it can be predicted that a common vaccine could be created. A recombinant
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DNA (rDNA) vaccine has the potential to eliminate many of the obstacles that limit the testing
and potential eradication of brucellosis.
Recombinant DNA technology joins together DNA molecules from different organisms
through molecular techniques to create genetic material from multiple sources, creating
sequences that would not otherwise be found in the genome. Vaccines can be composed of
plasmid DNA (pDNA), and other components, which can encode the antigen of interest under
the control of a promoter and is easily replicated within bacteria (Fioretti et al. 2010). Plasmid
DNA is self-replicating, circular DNA that exist extrachromosomally in bacteria (Liu 2003).
DNA vaccines typically consist of bacterial plasmids that are constructed to express protein
following the in vivo administration and transfection of cells (Liu 2011). They can be designed to
encode not only secreted proteins but also the transmembrane portion of the protein to elicit a
greater immune response.
While there are many possibilities associated with rDNA vaccines, there are downsides
when it comes to the construction and usage of this vaccine type. The main issue being the poor
immunogenicity of DNA vaccines in larger animals and humans. One reason it is difficult to
elicit a response in larger animals and humans is because of the amount of DNA required, which
raises concern over potential cost issues. Due to the structure of rDNA vaccines, the DNA needs
to be translocated to the nucleus for transcription followed by translation in the cytoplasm, which
poses a potential issue. The plasmid needs to be transported across the nuclear membrane to
achieve transcription and translation within the transfected cell. This has proven difficult and has
raised safety concerns as well about the stability of integration of transfected DNA into the
genome of some cells (somatic or germ), which has the potential to cause dysregulated gene
expression and/or mutations. There is also the potential of reduced transfection efficiency due to
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plasmid size and its difficulty in crossing the nuclear membrane. The longer the sequence used
for the plasmid, the more potential there is for a cross over event or homologous recombination.
There are currently no rDNA vaccines approved for use in humans, but there are some for
veterinary usage including one for West Nile Virus in horses and canine melanoma (Atherton et
al. 2016). There are a total of three DNA vaccines licensed for veterinary use and one DNA
plasmid licensed for gene therapy in swine (Liu 2011). The potential issue of size of the recipient
of the DNA vaccine was challenged when the West Nile Virus vaccine was proven successful in
horses. DNA vaccines can be proven more useful in humans and larger animals when the right
antigen (one that is intrinsically immunogenetic) is successfully determined for specific species
for certain vaccines. It was determined that there were therapeutic and prophylactic effects
associated with rDNA vaccines and potential immunogenicity was detected in humans. Wang
and colleagues were able to demonstrate induction of cytotoxic T lymphocyte (CD8+) cell
responses in primates to a plasmid encoding for Plasmodium falciparum (Wang et al. 1998). It
has been shown in other trials that there is an induction of cellular and humoral responses but not
significant enough to elicit meaningful clinical benefits. One potential reason for this is that
studies have shown most DNA vaccines remain localized at the site of injection and a minor
amount of the DNA is spread throughout the body and has been detected in other organs (Manam
et al. 2000). The potential immunogenicity of the DNA itself in DNA vaccines was an initial
concern due to the possible trigger of autoimmune diseases. However, through preclinical and
clinical trials of a variety of DNA vaccines they appear to be safe with little to no evidence of
DNA inducing anti-DNA responses (Liu 2011). Despite these barriers to success, rDNA vaccines
remain the target vaccination method for vaccine-based immunotherapeutic strategies for
treatments of infections, cancer, allergies, and autoimmune diseases.
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DNA vaccines have been proven safe in many clinical trials, including those for humans and
animals due to the lack of antibody response against prokaryotic components of the DNA
vaccine and any adverse effects associated with rDNA vaccines are limited to a mild local
reaction at the injection site. These vaccines are also more cost effective to produce and easy to
manufacture on a large scale. They are easily manufactured because the process is generic in
comparison to the process that is required for the manufacturing of attenuated vaccines, which
makes construction of rDNA vaccines rapid, and this can be critical for vaccinating against
potential pandemic threats (Liu 2011). The vaccines can maintain the immunological aspects
necessary for the pathogen while excluding other undesirable proteins or immune responses.
They are safe to handle because there is no need to handle the virulent pathogen or manipulate it
for manufacturing needs because the genes encoding the antigens are constructed without the
pathogen.
One concern is about the possibility of stable integration of transfected DNA into the
genome of either somatic cells or germ cells. This could cause dysregulated gene expression and
mutations. Wang and coworkers were concerned about unwanted immune effects due to a DNA
vaccine, so they repeated several experiments with intramuscular injections in primates to review
the results in animals. A long-term reporter expression was observed but the injections did not
induce any anti-DNA antibodies in the primates (Wang et al. 2004).
An additional safety issue associated with DNA vaccines is the potential for prokaryotic
components of the vaccine to be incorporated into the genome. For example, an antibiotic
resistance gene due to the incorporation of such genes in the backbone of the vector of DNA
vaccines. Antibiotic resistance occurs when bacteria develop the ability to survive and continue
replicating in the presence of the drugs designed to terminate them. Here, the concern is the
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integration of an antibiotic resistance gene in the backbone of a DNA vaccine vector leading to
the vaccinated individual being exposed to an antibiotic resistance gene, which could lead to
horizontal gene transfer (HGT). Horizontal gene transfer is the movement of genetic information
between organisms. This process is one of the ways that antibiotic resistance genes can spread
among bacteria thus increasing the number of individuals exposed to the antibiotic resistance.
Horizontal gene transfer is not only a concern because it increases the number of individuals
exposed to a resistant gene, but also because this process can occur in many bacterial lineages
resulting in a diverse population of strains (Burmeister 2015).
DNA vaccines can be utilized as a basic tool for research and the creation of antibodies
and have been used to produce monoclonal and polyclonal antibodies (Liu 2003). Generally,
antibodies are more effective when they are made against surface or envelope structures. The
technology of DNA vaccines allows the epitopes within the vaccine to be designed specifically
to these regions. With DNA vaccines the antigens will have mammalian glycosylation and other
post-translational modifications, which ensures they will more closely resemble the protein
during viral/bacterial infection (Liu 2011). Plasmid DNA can easily be utilized in vivo or in vitro
which helps in the testing of potential vaccines and manipulation of the product.
Infectious agents typically utilized in killed or live-attenuated vaccines can pose a threat
of bioterrorism through the misuse of these infectious agents including some species of Brucella;
B. suis, B. melitensis, and B. abortus. In the case of bioterrorism, it would be beneficial to have
vaccines not only with increased safety and speed in which they can be manufactured, but also
safety when handled by the public (Liu 2003) and that can be readily shipped to places in need
due to the lack of cold storage requirements. DNA can be stored at room temperature for up to a
year if harvested in the proper sterile conditions, which is in contrast from live vaccines that
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require cold for storage and for global transport, making them more difficult to use in less
developed countries (Haidari et al. 2013). Due to the generic manufacturing process of rDNA
vaccines compared to the current process, they can be created at an accelerated rate. The lack of
infectious agent in rDNA vaccines means they do not have the capability to revert to a virulent
phenotype like currently available live-attenuated vaccines, making them safer to manufacture
and be handled by the public. Live-attenuated vaccines are derived from the “wild” or diseasecausing bacteria or virus. The wild type is weakened in a laboratory typically through repeated
culturing, i.e., serial passage in tissue culture media to transform the wild strain into an
attenuated strain (Plotkin 2003). With an rDNA vaccine, the need for serial passages of an
infectious agent in a laboratory setting is eliminated thus increasing the safety of manufacturing
rDNA vaccines.
Recombinant DNA vaccines have the potential to induce an innate and adaptive immune
response and target the arms of the immune system: antibodies, helper T cells, and cytotoxic T
lymphocytes (CTLs) (Liu 2011). By utilizing a CTL response, a vaccine can directly target and
kill the infected cells, as opposed to killing the invading virus or bacteria. Cytotoxic T
lymphocytes can focus on antigens i.e., epitopes of proteins that are highly conserved that are not
accessible to antibodies. An epitope is the part of an antigen molecule to which an antibody
attaches itself. The advantage of utilizing epitopes that are conserved between different strains of
a pathogen, and thus less likely to mutate, is that it has the potential to make the vaccine more
broadly effective. To elicit a CTL response, the antigen needs to be present in the cytoplasm of
an antigen presenting cell (APC).
Vaccines are typically delivered in many ways including but not limited to intramuscular,
intradermal, and subcutaneous injections. These injections specifically address monocytes,
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keratinocytes, and APCs. DNA vaccines could directly target APCs. Antigen presenting cells
present peptides to Major Histocompatibility Complex I and II (MHC I/II) of a vaccinated
individual. Since what is encoded in DNA plasmids are derived from bacteria, they can stimulate
the innate immune system by interacting with toll like receptors (TLR) that can be found on
APCs (Fioretti et al. 2010). This non-specific immune response can directly or indirectly present
the antigen to APCs. The antigen encoded in the DNA vaccine can be produced by the host cell
and stimulate a direct immune response from APCs or non-APCs can take up the antigen and be
transferred to APCs leading to cross priming of the immune system (Fioretti et al. 2010).
Antigen presenting cells that have picked up an antigen can travel to the draining lymph nodes
and present the antigen to naïve T lymphocytes inducing both a humoral and cellular immune
response. Targeting multiple aspects of the immune system has been key when designing rDNA
vaccines.
The optimization of the plasmid itself of an rDNA vaccine mainly focuses on the promoter,
backbone, antigen, and an adjuvant. The promoter is a sequence of DNA that defines where
transcription of a gene by RNA polymerase begins. It leads to the initiation of transcription by
RNA polymerase in which DNA is transcribed to mRNA and is then translated into a functional
protein. Promoters are typically located upstream or at the 5’ end of the transcription initiation
site. The promoter could be a hybrid viral/ eukaryotic promoter and contain APCs specificity for
best results. Hybrid promoters have been previously shown to prevent transcriptional silencing.
Viral promoters can be subjected to methylation-mediated inactivation, however; hybrids and
eukaryotic promoters can remain active regarding long term activation (Hobernik and Bros
2018). There are different promoters that are typically utilized when using DNA technology, one
of which is the Cytomegalovirus (CMV) promoter. This promoter region is responsible for the
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initiation of transcription, by containing a binding site for RNA polymerase. The CMV promoter
has high levels of transient gene expression and works in many different cell types. The higher
levels of expression demonstrated by the CMV promoter outweighs the fact that other promoters
have a higher selectivity for dendritic cells (DC) (Moulin et al. 2012). Dendritic cells are targeted
because they constitute most of the APC population when in an activated state. CD11c and
dendrocyte expressed seven transmembrane proteins (DC-STAMP) are promoters that have a
marker specific to DC. However, the CD11c promoter has been shown to mount an insignificant
CTL response when utilized in an rDNA vaccine. In the same study DC-STAMP was expressed
in immature human and mouse cells and was down regulated in response to maturation.
The antigen should be codon optimized for specificity to the recipient of the vaccine, there
should be fusion with an invariant chain, and a combination of different antigens should be
included: MHC I and MHC II. An adjuvant is utilized to draw APCs to the site of injection to
increase the uptake of the vaccine and the presentation to MHC I/II. Antigen presentation/
recognition can be an issue, which is why epitope specific changes in the antigen to increase
MHCI and MHCII affinity should be included. The adjuvant should include an adaptor and/ or
transcription factors, APC/T stimulatory cytokines or chemokines, and to ensure the coexpression of an antigen and the molecular adjuvant by the transfected cells, both sequences
need to be incorporated into the DNA vaccines in cis. Not all vaccines utilize an adjuvant in the
design, some are paired with adjuvants that are injected simultaneously with the vaccine.
The vector backbone comprises the part of the DNA vaccine that is not required for
eukaryotic expression and it should include an immunostimulatory sequence, a nuclear
localization site (NLS), A/T rich sequences, and potentially minicircles. A minicircle is a small
circular replicon that lacks a bacterial origin of replication and antibiotic resistance genes, which
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allow for greater efficiency in transfection and longer epitope expression. Successful transfer of
DNA into a cell’s nucleus for subsequent expression is an obstacle especially in non-dividing
cells like APCs. DNA sequences such as the simian virus (SV) 40 enhancer region was identified
as being able to mediate nuclear translocation. Due to this, SV40 and similar sequences have
been included in vector backbones for DNA vaccines. Studies have shown that the overall size of
the vector is inversely related to transfection efficiency. Eliminating the prokaryotic portions of
the DNA vaccine that are unnecessary will yield minicircles and increase chances for successful
transfection.
By utilizing a rDNA vaccine, we eliminate the need for an attenuated strain to be injected
into an animal, thus allowing the current serological tests to accurately distinguish between an
animal that has been vaccinated and an animal with a live Brucella infection. It could also allow
the vaccine to be administered to pregnant females because it is not expected to harm the fetus. A
rDNA vaccine utilizes epitope sequences that are recognized by the immune system to elicit an
immune response. Epitopes from B. abortus were chosen for an rDNA vaccine, but because of
the genomic similarities it can be said that there is potential for protection from brucellosis
infection among varying species of animals.
Hypothesis: It is being proposed that both Brucella abortus vaccine 3 (BabV3) and
Brucella abortus vaccine 4 (BabV4) will elicit an immune response with no significant
difference between the responses based on the epitope length. Alternatively, BabV3 will elicit a
greater immune response due to containing longer epitopes and thus will create a greater overall
immune response within an animal.
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Alternative outcome: It is being proposed that neither BabV3 nor BabV4 vaccine elicits
an immune response within an animal regardless of epitope length. Alternatively, BabV4 will
elicit a greater immune response due to the shorter epitopes.
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Chapter 1. A Bioinformatic Approach to Recombinant DNA Vaccine Design
Aim one: To determine epitopes from Brucella abortus and design a vaccine that has the
potential to stimulate the immune system.
Aim two: To successfully build the vector and confirm correctness through DNA sequencing.
1.1. Introduction
In comparison to other conventional methods of vaccination, DNA vaccines are more
stable, cost effective, easy to manufacture, and safe to handle. DNA vaccines have been utilized
in veterinary medicine with 3 current vaccines approved by the USDA and the FDA and research
currently being done on the use of DNA vaccines in humans. Due to the potential infective
nature of some conventional vaccines that contain live-attenuated bacteria, the use of DNA
vaccines is ideal. Since DNA vaccines are based on purified plasmid DNA (pDNA), they are
non- infectious and are unable to replicate within a vaccinated host. Therefore, the vaccine will
not cause any harm or disease to the host. Instead ensuring that when the host is confronted with
the infectious agent, the immune system can respond appropriately (World Health Organization
2005).
One advantage that DNA vaccines offer is their ability to target antigen presenting cells
(APC) near the site of injection. With the ability to transfect these cells directly, it will increase
the likelihood that the antigen is presented to the immune system and a suitable immune
response is created. After injection, the antigen is expressed, processed, and loaded in parallel
onto Major Histocompatibility Complex I and II (MHC I/II), which then presents the antigen to
APCs. Antigen presenting cells migrate into draining lymph nodes and can prime cytotoxic T
lymphocytes (CD8+) and T helper cells (CD4+) when natural activation of the immune system
occurs.
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The safety of DNA vaccines has been proven through several clinical trials and has been
emphasized by the lack of antibody response against prokaryotic parts of the DNA vaccine, such
as the antibiotic resistance genes. Overall, clinical trials utilizing DNA vaccines have shown
sufficient induction of cellular and humoral responses but not enough for necessary clinical
benefits. Due to this, most DNA vaccine optimization strategies focus on an increase in the
immunogenicity of the vaccine itself to produce a greater immune response while also looking at
optimization of delivery of the vaccine to APCs, which can aid in helping improve
immunogenicity of the vaccine. This optimization of vaccine design should focus
primarily on the promoter, antigen, backbone, and the use of an adjuvant.
Antigen presenting cells present MHC I and MHC II epitopes to CD8+ and CD4+ cells
respectively (Belizario et al. 2016). While single epitope vaccinations have been shown to induce
protective immune responses, including multiple epitopes and antigens may result in a more
complete response and increased protection (Zhao et al. 2013; Ichihashi et al. 2011; DiMarchi et
al. 1986). Multi-epitope vaccines are also able to provide wide population coverage, protect
against pathogens with complex life cycles, and induce cross protection (Shen et al. 2016; Zhao
et al. 2012; Hashish et al. 2013). It is possible to simultaneously prime responses to multiple
specific MHC I epitopes with a single MHC II helper epitope (Oseroff et al. 1998). It has been
shown that a single short or long peptide containing intrinsic epitopes with broad MHC binding
potential or MHC I and II epitopes specific for multiple MHC alleles can produce a strong
immune response (Oseroff et al. 1998 and Bharadwaj et al. 1998). Immunization with single
epitopes, multiple epitopes, and immunodominant regions of antigens has been shown to provide
protection against brucellosis in mice (Afley et al. 2015 and Stevens et al. 1994). The
development of both the specific cytotoxic and antibody response is heavily influenced by CD4+
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cell interactions with CD8+ cells and B cells, respectively, indicating that protection induced by
epitope-based vaccines is maximized when MHC I, MHC II, and B cell epitopes are all present
(Yang et al. 1991 and Lowenadler et al. 1992). Immunization with MHC II epitopes, also known
as CD4+ helper T cell epitopes, has been shown to induce protection against pathogens and
enhance the immune response towards MHC I and B cell epitopes and are therefore considered
to be crucial in the development of epitope-based vaccines (Hughes et al. 2012 and Jardim et al.
1990). A disadvantage of this reliance of MHC II epitopes is that failure to elicit a sufficient
CD4+ T cell response may result in lower immunogenicity of the vaccine as a whole (An et al.
2000). The use of promiscuous MHC II epitopes, regions dense with multiple MHC II epitopes,
or long peptide sequences containing multiple epitopes has been successful at overcoming this
issue (Gomes et al. 2016; Perlaza et al. 2001; Ding et al. 2009). Optimal CD4+ enhancement of
B or CD8+ cell response is achieved when the epitopes are collinearly linked (Roehrig et al.
1992; Shirai et al. 1994 and 1996). On farms where small ruminants and cattle intermingle, B.
melitensis may be transmitted between the two species; therefore, a vaccine capable of inducing
cross protection against the six main Brucella spp. is desired (Benkirane 2006 and Álvarez et al.
2011). Multi-epitope vaccines induce cross protection by the delivery of several antigens at once
or concentrating the immune response on a small number of conserved epitopes rather than
polymorphic epitopes (Sayes et al. 2012; Wongkidakaran et al. 2016; Ntumngia and Adams
2012). DNA/DNA hybridization studies revealed that members of the genus Brucella share over
90% homology (Hoyer and McCullough 1968), and other studies have shown that immunization
with immunodominant conserved regions of antigens is effective at inducing cross protection
(Tadepalli et al. 2016).
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Brucellosis is a zoonotic disease that effects mammals, typically causing reproductive
issues in animals such as placentitis followed by abortion in females and infection of the
epididymis in males. It is characterized by malaise and flu-like symptoms in humans. It is caused
by several different species of the gram-negative intracellular bacteria and can be spread through
contact with infected animals or through consumption of unpasteurized dairy products from
infected animals. Due to the large number of people and animals infected worldwide each year,
an rDNA vaccine was designed against this bacterium.
1.2. Materials and Methods
1.2.1. Epitope selection
Several proteins from the B. abortus genome were identified as being immunogenic and were
analyzed through a tool called EpiMatrix which gave a score associated with each protein
(EPICC 2022). The EpiMatrix Score was derived from the number and intensity of the
EpiMatrix Hits normalized for the length of the protein meaning, the Score is the excess or
shortfall in predicted aggregate immunogenicity relative to a random peptide standard. The
proteins were analyzed regarding both MHC I and MHC II. Two separate, but similar, vaccines
were developed and are named, Brucella abortus Vaccine 3 (BabV3) and Brucella abortus
Vaccine 4 (BabV4). Within the B. abortus genome epitopes were chosen due to their high
immunogenicity and likelihood of being readily recognized by IgG and IgM antibodies of the
immune system. The proteins from which epitopes were identified from are Brucella Protein 26
(BP26), Outer Membrane Protein 19 (Omp 19), Omp 2b, Omp31b, Super oxide dismutase
(SOD), and 2 heat shock proteins GroEL and HtrA. Three unique epitopes were chosen from
BP26, two were chosen from Omp2b, and two portions were utilized from Omp31b. All other
proteins were chosen for the use of one specific epitope sequence.
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BabV3 and BabV4 contain seven epitopes total, listed in Tables 1.3. and 1.4. BabV3 is
approximately 1,000 base pairs longer than BabV4 due to the additional epitope length. The
epitopes range in length from 75 base pairs to 238 base pairs. Both vaccines were designed
without the lipopolysaccharide (LPS) which is present in the smooth strain of Brucella. This is
similar to the live-attenuated vaccine, RB51, which is also lacking LSP.
1.2.2. Other vaccine components
The promoter that was chosen for this vaccine is the Cytomegalovirus (CMV) promoter.
Integrated DNA Technologies’ (IDT) codon optimization tool was used to codon optimize the
vaccine reading frame. Codon optimization is done to tailor the vaccine to the intended target, in
this case bovine. There are two different free rotational spacers (FRS) chosen for the vaccine and
they were added to allow proper folding of the proteins. The FRSs have a higher
guanine/cytosine content than other components within the vector (McGee 2017).
The sequence from Simian Vacuolating virus 40 is (SV40) responsible for the nuclear
localization and has been determined and used for this vector (Dean 1999). For this vaccine
design the SV40 Poly A sequence was used to cause successful termination of transcription as
well as the addition of a poly A tail (Li et al. 2013). A super oxide dismutase (SOD) portion,
which is a molecular adjuvant, was also included in the vector backbone. A poly A signal
sequence was used at the end of a gene that causes the termination of transcription. The poly A
functions by causing the detachment of the RNA polymerase (Kim et al. 2017). The Con
albumin signal sequence was chosen because of the previous work conducted in our lab.
There are two antibiotic resistance genes incorporated into the vector for in vitro testing. The
puromycin antibiotic resistance gene was incorporated for selection during cell culture, however,
all antibiotic resistance genes will need to be removed for commercial applications.
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Table 1.1 Major Histocompatibility Complex Class I Protein Summary
Protein Label
Length
EpiMatrix Hits

EpiMatrix Score

OMP31

261

79

30.11

OMP2b

375

97

21.99

SOD

173

50

6.75

BP26

250

69

-9.05

GROEL

546

150

-11.82

HTRA

513

124

-22.29

OMP19

177

35

-28.93

Source: (EPICC 2022)

Table 1.2. Major Histocompatibility Complex Class II Protein Summary
Protein Label
Length
EpiMatrix Hits

EpiMatrix Score

OMP31

261

101

-12.67

OMP2b

375

151

-8.27

SOD

173

51

-38.62

BP26

250

90

-17.02

GROEL

546

168

-34.03

HTRA

513

142

-42.03

OMP19

177

47

-43.52

Source: (EPICC 2022)
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Table 1.3. BabV3 Epitopes
Protein
Amino Acid Sequence of Epitope(s) Chosen
BP26
1. ASNFLAASFSTMLVGAFSLPAFAQ
2. SPDMAILNLSVLRQAKTAREAMT
3. GGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADA
GroEL
1. LSPYFVTNPEKMVADLEDAYILLHEKKLSNLQALLPVLEAVVQTSKPLLIIEDVEGEALATLVV
NKLRGGLKIAAVKA
HtrA
1. SGDVIVSVNNQTVKTAGDINKAITAAEKSGRKAVLLQLQSNDQSRFVALPINQE
Omp19
Omp2b

1. MGISKASLLSLAAAGIVLAGCQSSRLMTFKNLLGASLVAVITSTSAY
1. MPRPIFNFDWRSEMKIKSLLLGSAAALVAASG
2. QFSVWLQGAYSSAATPDQNYGQWGGDWAVWGGLKYQATQKAAFNLQ

Omp31b

1. MFSLKGTVMKTALLASVAMLFTSSAMAADI
2. GVEYAVTNNWTLKSEYLYTDLGKRSFNYIDEENVNINMENKVNFHTVRLGLNYK

SOD

1. MAFELPALPYDYDALAPFMSRETLEYHHDKHHQAYVT

Table 1.4. BabV4 Epitopes
Protein
Amino Acid Sequence of Epitope(s) Chosen
BP26
1. ASPDMAILNLSVLRQAKTAREAMT
GroEL
1. LSPYFVTNPEKMVADLEDAYILLHEKKLSNLQALLPVLEAVVQTSKPLLIIEDVEGEALATLV
VNKLRGGLKIAAVKA
HtrA
1. SGDVIVSVNNQTVKTAGDINKAITAAEKSGRKAVLLQLQSNDQSRFVALPINQE
Omp19
Omp2b
Omp31b
SOD

1.
1.
1.
2.

MGISKASLLSLAAAGIVLAGCQSSRLMTFKNLLGASLVAVITSTSAY
MPRPIFNFDWRSEMKIKSLLLGSAAALVAASG
MFSLKGTVMKTALLASVAMLFTSSAMAADI
MAFELPALPYDYDALAPFMSRETLEYHHDKHHQAYVT

25

Figure 1.1. BabV3 epitope sequence compared to the BabV4 epitope sequence being utilized in the vaccines. This figure shows the
differences in epitope length among the two vaccines with BabV3 being ~1,000 base pairs longer than BabV4.
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1.2.3. Testing for vector completeness
Competent E. coli cells (New England Biolabs, Ipswich, MA C2992) were utilized for
transfection and the transfection was performed as follows: Cells were thawed on ice and 1μl of
the IDT vector for the open reading frame (ORF) of BabV3 and BabV4 was added to two
separate tubes containing 50 μl of CaCl2 competent cells each. Mixture was incubated on ice for
30 minutes, heat shocked at 42°C in a water bath for 30 seconds and incubated on ice for 5
minutes. Then, 950 μl of room temperature SOC media was added to each tube and the tubes
were placed in a shaking incubator at 37°C for 60 minutes. One hundred microliters of each
transfection were spread on a half strength super broth plate (BD, Franklin Lakes, NJ) to be
grown overnight in an incubator at 37°C. The colonies were later picked, and the DNA isolated
through a ZR mini prep kit (Zymo Research, Irvine, CA). An agarose gel was run to visualize the
size of the DNA fragment in the mini preps. The mini preps labeled BabV3 1-6, BabV4 1-1, and
BabV4 2-9 appeared to be the correct size when compared against a supercoiled ladder. Once
this component was confirmed correct the DNA was ligated to the CMV PBS Puro backbone
(CPP) which was previously created in our lab.
A test digest utilizing Fast Digest enzyme SalI (ThermoFisher Scientific, Waltham, MA)
was performed and a SYBR Safe DNA gel (ThermoFisher Scientific, Waltham, MA) was run to
confirm exactness and extract the correct piece of the vaccine for ligation. A SYBR safe stain is
a DNA stain that is for visualization on agarose gels and can be utilized via UV excitation
without damaging the DNA. The ligation of BabV3 and BabV4 with CPP went as follows: 4.5 μl
of the BabV3/ BabV4 DNA was mixed with 1.5 μl of CPP DNA and heated to 42°C in a water
bath for 2 minutes and then snap cooled at -30°C. Ten microliters of 2X Quick Ligase buffer and
1μl of Quick Ligase (New England Biolabs, Ipswich, MA) were added to the tubes as well and
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the mixtures were incubated at room temperature on the counter for 60 minutes before the
transfections began.
The subsequent transfections took place following the previously mentioned transfection
protocol except that 5 μl of each ligation (BabV3 and BabV4) were mixed with 50 μl of CaCl2
competent cells opposed to their respective IDT vectors. Mini preps and a gel were performed as
mentioned previously to determine successful ligation of BabV3/BabV4 with CPP.
Two colonies, BabV3 colony 1-6 and BabV4 colony 2-9, were chosen because they
appear to be the correct size but required further testing to confirm successful ligation between
BabV3 or BabV4 and CPP. A test digest with Fast Digest enzyme BshI (ThermoFisher
Scientific, Waltham, MA) was conducted to determine successful ligation. A Polymerase Chain
Reaction (PCR) was performed on BabV4 to determine ligation because the test digest was
unsuccessful. A ZymoPure Midi prep (Zymo Research, Irvine, CA) was performed on BabV3
colony 1-6 to isolate a higher quantity of DNA to be sequenced.
1.3. Results
Specific epitopes for the BabV3 and BabV4 vaccine (Tables 1.3 and 1.4) were analyzed
utilizing an EpiMatrix analysis (Tables 1.1 and 1.2). These epitopes for BabV3 and BabV4
(Figure 1.1) were ligated to the CPP backbone to create the complete vector for testing.
Successful ligation of BabV3 1-6 to CPP was confirmed through the test digest (Figure 1.4). A
PCR was conducted on BabV4 to determine successful ligation and correct size of the amplicon
to determine if it was the approximate size of BabV4 plus CPP, showing successful ligation
(Figure 1.5). If it was the size of either of the components alone, this would prove that the
ligation was unsuccessful.
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Figure 1.2. The complete Brucella abortus Vaccine 3 plasmid design with a CMV PBS PURO backbone.
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Figure 1.3. The complete Brucella abortus Vaccine 4 plasmid design with a CMV PBS PURO backbone.
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Two bands of DNA were visualized via a SYBR safe gel, so both bands were extracted and
sequenced to determine which band contains the BabV4 insert. The sequencing was used to
evaluate the BabV4 vaccine in the CPP backbone. DNA samples were submitted to the Gene
Probes and Expression Systems Laboratory/LSY BioMMED (Gene Lab Louisiana State
University) for sequencing, analyzed using SnapGene, and determined to be correct in containing
both BabV3 and CPP (CPPB3). Additionally, one DNA fragment from BabV4 colony 2-9 was
also confirmed to be correct in containing both BabV4 and CPP (CPPB4) (Figure 1.5). Through
primer specific sequencing of isolated DNA from BabV3 and BabV4 midi preps was confirmed
that all intended portions of the vector were present in the conformation for which they were
designed (Figures 1.2 and 1.3).
1.4. Discussion
Both vaccines were constructed using the same components, except for the length of the
immunogenic epitopes selected from B. abortus that were incorporated into the open reading
frame. The epitopes chosen were from proteins identified in other studies to be immunodominant
(Jain et al. 2014; Fiorentinio et al. 2008; Campos et al. 2002; Lim et al. 2012; Yang et al. 2005
and 2007; Wang et al. 2014; Clapp et al. 2001; Pasquevich et al. 2011 and 2009; Tadepalli et al.
2016; Abkar et al. 2015 and 2017; Vizcaíno et al. 1996 and 1997; Shirdast et al. 2021; Nazifi et
al. 2019; Cassataro et al. 2005; Hansen et al. 1988; Hindersson et al. 1987; Lin et al. 1992; Roop
et al. 1992 and 1994; Sekhavati et al. 2015; Al Dahouk et al. 2007; Amirmozafari et al. 2008; Li
et al. 2013 and 2019; Lin et al. 1995 and 1996; Golshani et al. 2016; Cloeckaert et al. 2002 and
1996; Paquet et al. 2001; Ficht et al. 1988, 1989, 1990; He and Xiang 2010; Sung et al. 2014;
Golshani et al. 2016; Pallen and Wren 1997; Elzer et al. 1994, 1996; Phillips et al. 1995;
Robertson et al. 1996).
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1 2
Figure 1.4. In lane 1 is the test digest with BshI utilizing DNA from BabV3 colony 1-6 and lane 2 contains a 1kb ladder for reference.
The digested band shows the correct size DNA for the BabV3 1-6 insert ligated to the CMV PSB Puro backbone.

1

2

3

4

5

6

Figure 1.5. In lane one is a 1kb ladder for reference and in lane 4 is a PCR on BabV4 colony 2-11 and in lane six is a PCR on
BabV4 colony 2-9.
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First, the literature was surveyed to determine proteins known to stimulate an immune
response; particular attention was paid to proteins shown to stimulate the immune system by
more than one research lab (Jain et al. 2014; Fiorentinio et al. 2008; Campos et al. 2002; Lim et
al. 2012; Yang et al. 2005 and 2007; Wang et al. 2014; Clapp et al. 2001; Pasquevich et al. 2011
and 2009; Tadepalli et al. 2016; Abkar et al. 2015 and 2017; Vizcaíno et al. 1996 and 1997;
Shirdast et al. 2021; Nazifi et al. 2019; Cassataro et al. 2005; Hansen et al. 1988; Hindersson et
al. 1987; Lin et al. 1992; Roop et al. 1992 and 1994; Sekhavati et al. 2015; Al Dahouk et al.
2007; Amirmozafari et al. 2008; Li et al. 2013 and 2019; Lin et al. 1995 and 1996; Golshani et
al. 2016; Cloeckaert et al. 2002 and 1996; Paquet et al. 2001; Ficht et al. 1988, 1989, 1990; He
and Xiang 2010; Sung et al. 2014; Golshani et al. 2016; Pallen and Wren 1997; Elzer et al. 1994,
1996; Phillips et al. 1995; Robertson et al. 1996). Second, the protein amino acid sequence was
analyzed for likely epitopes, and third, amino acid sequences were translated to DNA and codon
optimized for the target animal.
An epitope is the part of an antigen molecule to which an antibody attaches. The goal in
choosing these antigenic epitopes was to have protein folding mimic proteins from the whole
Brucella bacterium to mount a biosimilar immune response within the body. A bioinformatics
approach was used to predict the epitopes most likely to produce an MHCI or MHCII response.
Each vaccine contained a specific insert, with different lengths of epitopes. The vaccines were
designed with different length epitopes to determine how much of the amino acid sequence is
needed to mimic the natural conformation seen in the whole bacterial organism and thus
stimulate an immune response. Testing two vaccines with different length epitopes will help
determine whether the size of the vector or the number of immunogenetic epitopes are the key
factor in producing a successful immune response within an animal. The size of the vector is
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important because it has been demonstrated that vector size is inversely correlated with
transfection efficiency. To combat this problem the goal was to eliminate the prokaryotic vector
components of the DNA vaccine that are required for replication in bacteria, but not essential for
mounting an immune response, yielding a minicircle as a final product. For these vaccines, the
promoter region allows for the transcription of the vaccine reading frame in the target cell. This
promoter region allows RNA polymerase to bind for the initiation of transcription and
transcribes the DNA into messenger RNA (mRNA) (Transcription/Translation – Promoters
2019). The CMV promoter, a ubiquitous promoter that functions in many different cell types,
was selected because of its high levels of constitutive gene expression.
Codon optimization was utilized in the creation of these vaccines and is mostly required
if the target antigen is of non-human origin because it can significantly enhance antigen
expression. There are 20 different amino acids and 64 codons. Since there are multiple codons
for many amino acids, some organisms have a bias towards specific codons for these amino acids
(Karaçay 2018). The IDT codon optimization tool also reduces complexities that interfere with
the construction of the vaccine. An example of these complexities could be, if the encoded
antigen is shown to be expressed in low amounts there could be an issue with antigen
presentation/recognition thus producing an obstacle to a sufficient immune response. This issue
would be presented during codon optimization and addressed through epitope specific changes in
the antigen to increase MHC affinity. Affinity is the binding strength in which one fragment,
antigen binding (Fab) portion of an antibody would bind to an epitope region. The design of an
antigen encoding expression unit includes the selection of immunogenic antigen derived from
one or multiple proteins to be presented via MHCI/II to produce parallel CD4+/CD8+ T cell
activation, codon optimization and strategies to boost MHCII antigen presentation. Antigens
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with a higher half-life have been shown to induce a stronger CD8+ response which increases
immunogenicity. The FRS were placed between the epitopes to allow the protein to mimic its
natural structure and produce conformational epitopes similar to the native antigen (McGee
2017).
One of the major concerns with DNA based vaccines is the nuclear uptake of the
intended genetic payload. The NLS is a sequence of DNA that is recognized by nuclear transport
protein of the transportin family and can aid in DNA transport across the nuclear membrane or
envelope. One of the most heavily researched NLS sequences is from SV40, T antigen. The
nuclear envelope is a major barrier for nuclear uptake of plasmids and represents a problem of
non-viral gene delivery. If the genetic payload is too large for entry through the nuclear pores,
then one of the mechanisms for nuclear uptake is for the transfected cell to undergo division,
wherein the nuclear envelope naturally disassembles. With the nuclear envelope broken down
during division, the DNA from the vaccine can naturally enter the nucleus after the cell exits
mitosis; however, the optimal targets for this vaccine are APCs.
To determine MHC I and MCH II T-cell epitopes of B. abortus and evaluate their
potential effectiveness in a vaccine, a mouse model was utilized (Afley et al. 2015). The peptides
chosen for the experiment were designed using immunoinformatic tools and chosen based on
their ability to produce interferon gamma (IFN- γ) in in vivo studies. IFN- γ plays two crucial
roles in the event of a Brucella infection. It increases regulation of macrophage anti-Brucella
activity which is the main component of the protective response (Oliveira and Splitter 1996) and
it induces the expression of IFN- γ inducible genes, which are crucial for the development of
innate and adaptive immunity against Brucella.
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The Brucella spp. express an immunogenic 18.5-20 kDa periplasmic Cu/Zn superoxide
dismutase (SOD) (Onate et al. 2003; Retamal-Diaz et al. 2014; Tabatabai and Pugh 1994) a class
of enzymes which allow bacteria to survive the respiratory burst of phagocytes (Sriranganathan
et al. 1991 and Pratt et al. 2015). Brucella abortus SOD deletion mutants display reduced
survival during early infection in vivo (Tatum et al. 1992). Super oxide dismutase has been
utilized as a therapeutic agent against oxidative stress in the body and against reactive oxygen
species mediated diseases (Younus 2018). It has antioxidant capabilities due to its ability to
reduce free radical damage within the body. The SOD enzyme can serve as an anti-inflammatory
agent and may be useful as an inhibitory agent of neutrophil mediated inflammation for an
approach for ROS-dependent tissue damage induced by neutrophils (Younus 2018). RB51
vaccinated cattle and mice do not produce a humoral or cell-mediated immune response against
SOD (Stevens et al. 1994 and Vemulapalli et al. 2000), indicating that SOD is not a necessary
antigen for a protective immune response (Stevens et al. 1994). However, immunization with
SOD has been found to consistently grant protection against brucellosis when administered in the
form of either recombinant peptides, DNA vaccines, whole recombinant proteins, overexpression
mutants, or through co-immunization with other antigens (Hu et al. 2010; Yu et al. 2007;
Vemulapalli et al. 2002). In mice, DNA vaccinations encoding SOD have consistently induced
protection at two to four weeks following challenge and display a Th1 biased immune response
characterized by IFN-γ producing CD4+ cells, specific CD8+ cytotoxic activity, splenocyte
proliferation, and low or no detectable IL-10 and IL-4 (Singha et al. 2008; Munzo-Montesino et
al. 2004). SOD DNA vaccinated calves showed significant IgG1 and IgG2a titers and IFN-γ+
peripheral blood monocytes (PBMC) but no detectable TNF-α or IL-4 on stimulation with rSOD
or crude Brucella proteins (Saez et al. 2008). Mice vaccinated with the synthetic SOD peptide
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GGAPGEKDGKIVPAG, with or without adjuvant, showed significant protection two weeks
following B. abortus challenge (Tabatabai and Pugh 1994). The vaccine discussed was designed
to utilize the co-administration of an exogenous adjuvant. An adjuvant aids the upregulation of
antigen presenting receptors, co-stimulators, and pro-inflammatory mediators for efficient T cell
activation and polarization. Due to the intrinsic adjuvancy of pDNA and coupled with the codelivery of an established adjuvant there is the potential for stimulation of APCs upon injection
in the vaccines thus producing a better chance for an immune response to occur.
The protein, BP26, also known as Omp28 (Jain et al. 2014), is a 26 kDa periplasmic
protein of unknown function that is immunogenic and immunodominant in cattle, dogs, goats,
sheep, and humans (Fiorentino et al. 2008 and Campos et al. 2002). This protein is highly
conserved between B. melitensis, B. abortus, B. ovis, B suis and B. neotomae (Lim et al. 2012;
Yang et al. 2005; Wang et al. 2014). Brucella Protein 26 can induce both humoral and cellmediated responses and is protective as a subunit or DNA vaccine (Clapp et al. 2011 and Yang et
al. 2007). Immunization with recombinant BP26 in BALB/c mice resulted in approximately 2.6
logs of protection against B. abortus 10 days post-infection (Lim et al. 2012). DNA vaccination
with BP26 resulted in 1.16 log less CFU in the spleen of BALB/c mice when challenged with B.
melitensis (Yang et al. 2005). Twelve epitopes of BP26 are capable of inducing IFN-γ secretion
from PBMCs of sheep between 1 to 7.5 months after vaccination with B. melitensis M5-90
(Wang et al. 2014). BP26 DNA vaccination can produce IFN-γ and both specific CD4+ and
CD8+ cells in sheep and bison (Clapp et al. 2011 and Wang et al. 2014), suggesting this antigen
is a candidate for immunization in multiple animal and Brucella species.
Outer membrane protein 19 (Omp19) is an 18-19 kDa outer membrane surface exposed
lipoprotein that is associated with virulence and present in all biovars of the six classical
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Brucella spp. (Pasquevich et al. 2011; 2009). CD4+, CD8+ and antibodies specific to Omp19
can induce systemic and mucosal protection against brucellosis (Pasquevich et al. 2009 and
Tadepalli et al. 2016). Mice immunized with recombinant Omp 19 (rOmp19) or an
immunodominant region of Omp19 (amino acids 21 – 177) display systemic protection against
both B. melitensis and B. abortus when challenged (Pasquevich et al. 2009; Abkar et al. 2015;
Tadepalli et al. 2016). Sera from mice immunized with rOmp1921-177 protected macrophages
from cytopathic effects of both B. abortus and B. melitensis in vitro (Tadepalli et al. 2016),
suggesting that concentrating the antibody response on this region is an effective immunization
strategy. Recombinant Omp19 has also been shown to activate dendritic cells and provide
mucosal protection against B. abortus (Pasquevich et al. 2009; 2011).
Outer membrane protein 31 (OMP 31) is a 31-34kDa OMP that has been identified as a
minor OMP in B. abortus strains but is a major OMP in other Brucella spp. (Vizcaíno et al.
1997) especially B. melitensis and it is a promising candidate for a subunit vaccine against
brucellosis (Abkar et al. 2017). In a study by Vizcaíno and others, humoral and cellular immune
response to the protein BP26 and OMP31 were evaluated in M5-90 vaccinated Chinese merino
and Kazak sheep (Vizcaíno et al. 1997). Antibodies to BP26 or OMP31 were detected at low
levels, and specific IFN-γ response was quantified. Strongly reactive peptides derived from BP26
and OMP31 identified five T-cell epitopes (BP26-6, -8, -11, -12 and OMP31-23) common to
both sheep species, five species-specific epitopes (BP26-10, -18, -21 and -22 and OMP31-12)
and four animal-specific epitopes (BP26-15, -23, OMP31-6 and -21), which stimulated specific
IFN-γ response in vaccinated sheep (Wang et al. 2014). The expression of OMP 31 in all biovars
of B. melitensis, B. suis, B. ovis, B. canis, and B. neotomae was verified by an SDS-PAGE
followed by immunoblotting against the anti-Omp-31 mAb A59/10F09/G10 (Vizcaino et al.
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1997). Reference strains reacted in immunoblotting with the anti-Omp-31 mAb showing a
multiple banding pattern ranging from 28 to 34 kDa according to molecular mass protein
standards, which is characteristic for Omp-31 (Vizcaíno et al.1996). In a study surveying the
immunogenicity of Omp31 alone and paired with incomplete Freund’s adjuvant, the data
obtained from the cell proliferation assay showed that vaccination with Omp31 stimulated an
antigen-specific cell proliferative response, which could be further increased after oral
immunization with TMC/Omp31 nanoparticles. When challenged with B. melitensis 16M,
vaccinated groups of mice were found to be significantly protected in the group that was
vaccinated orally (Abkar et al. 2017). Outer membrane protein 31 is the major outer membrane
protein of Brucella and is considered as a protective antigen against Brucella infection (Shirdast
et al. 2021). Outer membrane protein 31 has been used as a DNA vaccine against B. melitensis
and B. ovis challenges. Also, some studies have shown that Omp31 can stimulate cellular and
humoral immune responses (Nazifi et al. 2019; Cassataro et al. 2005).
Heat shock proteins, including GroEL, have been found to be immunodominant targets of
both the humoral and cellular immune responses (Hansen et al. 1988; Hindersson et al. 1987; Lin
et al. 1992; Roop et al. 1992). The GroEL gene encodes an inner membrane protein of Brucella
and the molecular weight is approximately 60 kDa. This protein belongs to the heat shock
protein family, and as a chaperonin has an important role in the structure and folding of other
proteins. In response to macrophage phagocytosis, Brucella produces the GroEL antigen to
increase its survival. GroEL is one of the major antigens that stimulates the immune system
(Sekhavati et al. 2015). This antigen has an important role in disease cycle in humans and
animals (Al Dahouk et al. 2007). In a comparative study on two different strains of Brucella, the
HSP (GroEL) antigen was introduced as a good candidate for vaccine production and
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development of diagnostic kits (Amirmozafari et al. 2008). In a study by Li and others, the GroEl
gene of B. melitensis Rev l was a candidate for molecular analysis and epitope prediction.
Molecular analysis revealed that the GroEL sequence of B. melitensis Rev l is like other
Brucella spp. and since this gene is present in different species, it can be a good candidate for
stimulation of the immune system (Li et al. 2013). The immunodominance of GroEL is
presumably related to its abundant expression which is induced during infection of macrophages
(Lin and Ficht 1995). However, results from other intracellular pathogens have suggested the use
of GroEL homologs as potential vaccine candidates because of their potent antigenicity. To
evaluate the potential role of GroEL as a vaccine, the humoral immune response in cattle
vaccinated with B. abortus S19 was examined first. The immunoprotective capacity in mice was
subsequently characterized by challenge with B. abortus S2308 (Lin et al. 1996). Killed Brucella
cells release proteins including GroEL which are processed and presented on the surface of
macrophages. Generally, antigen processing takes place within the endosomes of macrophages
or other antigen-presenting cells. Processed antigen in combination with major
histocompatibility complex molecules are presented to T cells which stimulate an immune
response. In this context, GroEL would represent a potential target for natural killer cells;
however, similarities to host proteins may prevent such reactions (Lin et al. 1996).
Outer membrane protein 2b (OMP2b) along with OMP2a encode and potentially express
a 36-38 kDa porin protein (Golshani et al. 2016 and Cloeckaert et al. 2002). The two genes are
highly linked and share approximately 85% homology, but in opposite directions (Cloeckaert et
al. 1996); however, only OMP2b is utilized here because OMP2a is not present in B. abortus
(Cloeckaert et al. 2002; Paquet et al. 2001). Studies showed that the six main Brucella spp. can
be differentiated based on OMP2b (Ficht et al. 1988; 1989; 1990). OMP2b is an important
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component protein of the Brucella outer membrane and is highly immunogenic (Li et al. 2019).
In a study performed looking for T/B cell response, an IFN-γ ELISPOT assay showed that the TB combined epitope peptides of OMP2b activated T helper cell immune responses and have
immunogenicity and immunoreactivity (Li et al. 2019). A study focusing on identifying
protective antigens in Brucella demonstrated that OMP2b is a priority antigen for designing a
recombinant protein vaccine (He and Xiang 2010) and the results of a study done by Sung et al.
(Sung et al. 2014) showed that Omp2b may be a potential lipopolysaccharide-free protein for
developing diagnostic tests (Golshani et al. 2016).
High temperature requirement A (HtrA), a shock-induced serine protease that is active in
the periplasm of Escherichia coli (Pallen and Wren1997) and present in Brucella is thought to be
a 60kDA protein (Roop et al. 1994). Homologues of HtrA have been in a variety of bacteria and
in eukaryotes. Its primary function is the degradation of misfolded proteins in the periplasm
(Pallen and Wren 1997). The expression of htrA is regulated by a complex set of signal
transduction pathways, which includes an alternative sigma factor, RpoE, an anti-sigma factor,
RseA, a two-component regulatory system, CpxRA, and two phosphoprotein phosphatases, PrpA
and PrpB (Pallen and Wren 1997). Several biochemical and genetic studies indicate that bacterial
stress response proteases of the high temperature requirement A (HtrA) family represent
important components of cellular defense against oxidative killing (Baumler et al. 1994; Boucher
et al. 1996; Davies and Lin et al. 1992; Johnson et al. 1991; Li et al. 1996). In a study testing the
effect of the deletion of the htrA mutant, the reintroduction of the B. abortus htrA on pRIE1
(Elzer et al. 1994) restored resistance of PHE1 to killing by cultured murine macrophages to
wide-type levels, directly demonstrating the connection between the sensitivity of PHE1 to
killing by phagocytosis and the htrA mutation (Elzer et al. 1996). Mutations in the htrA genes
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of Salmonella, Brucella and Yersinia cause decreased survival in mice and/or macrophages,
and htrA mutants can act as vaccines, as cloning hosts and as carriers of heterologous antigens
(Pallen and Wren 1997). Based on earlier studies (Elzer et al. 1994; Phillips et al. 1995;
Robertson et al. 1996) its conﬁrmed that the Brucella htrA gene product protects intracellular
pathogens from oxidative damage and contributes to their resistance to killing by host
phagocytes.
The signal sequence is another important component within the vector and the con
albumin signal sequence was chosen to expose the protein/epitopes to the immune system. Con
albumin or ovotransferrin is the protein that occurs in egg whites and is the second most secreted
egg white protein produced indicating a highly efficient signal sequence. There is a pre and pro
portion to the signal sequence and they represent secreted proteins (Palmiter 1972). The pre
portion is secreted in the inner membrane of the cell and cleaved off while the pro portion is
secreted outside of the cell and passes through the membrane and is cleaved as well. This created
two cleavage points and a mature protein downstream, which gets folded and secreted. Once
there was a tool widely available to analyze signal sequences, the con albumin signal sequence
was analyzed, and it was shown that it has homology with almost every signal sequence
regardless of animal type for secreted proteins (Corden et al. 1980). Once this homology was
determined between con albumin and other signal sequence proteins it became acceptable to
utilize it in mammalian cells. The expressed proteins were used to keep the signal sequence as
natural as possible.
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Chapter 2. Determining Protein Expression in Varying Cell Lines
Aim1: To determine if CMV PBS Puro BabV3/ BabV4 can be readily expressed and detected in
a HEK 293 cell line vs. an Ovine Kidney cell line.
Aim2: To determine if BabV3 in an SXD backbone can be readily expressed and detected in a
HEK 293 cell line vs. a macrophage cell line.
2.1. Introduction
Cell culture is the removal of cells from an animal or plant and their subsequent growth
in a favorable artificial environment. The cells utilized in cell culture experiments can come from
either a cell line or strain that was previously established or can be taken directly from the tissue
itself (Harrison and Rae 1997). A cell line is established after the first subculture where it is
derived from primary cultures, which have a finite lifespan and as they are passaged, cells with
the highest growth capacity predominate resulting in a degree of genotypic and phenotypic
uniformity within the population. If a subpopulation of a cell line is then positively selected from
the culture by cloning or some other method, this cell line becomes a cell strain. A cell strain
often acquires additional genetic changes after the initiation of the parent line. Typically, cells
divide a limited number of times before losing their ability to proliferate which is a genetically
pre-determined event known as senescence and the cells have a finite lifespan. However, some
cell lines can become immortal through the process of transformation which can occur
spontaneously or can be chemically or virally induced. When a finite line undergoes
transformation and acquires the ability to divide indefinitely, it becomes a continuous cell line.
Human Embryonic Kidney (HEK) 293 cells are popular because of their ease of growth
and transfection and are typically utilized in transfection experiments. HEK 293 is derived from
human embryonic kidney cells grown in tissue culture and this line was initiated by the
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transformation of normal HEK 293 with sheared adenovirus 5 DNA. This transformation
resulted in incorporation of approximately 4.5 kilobases from the viral genome into human
chromosome 19 of the HEK cells. They are frequently utilized in experiments today because
they can produce proteins most like those that naturally synthesized by humans (Shaw et al.
2002). Likewise, an ovine kidney cell line was created (Matsuura et al. 2011) to be useful for
testing of viruses that effect cloven-hoofed animals. This cell line can be further utilized in
testing for protein production as well. The mouse macrophage cell line J774 is also being utilized
to determine the effect of the vaccine(s) on an immune system cell type (Unkeless 1979;
Mazumdar et al. 2021). Macrophages are immune system cells that reside in tissues and
differentiate from monocytes. They have a wide range of jobs that encompass the innate and
acquired immune functions and due to this wide range, they are a well-established model for cell
biology and immunology (Lam 2008). Since macrophage cell lines can be easily maintained and
manipulated, they were an ideal immune cell line to test rDNA vaccines. The vaccines were
tested in multiple cell lines to compare successful protein production and expression. It is
hypothesized that the HEK 293 cell line will more readily be transfected with and express the
DNA than the Ovine Kidney cell line and the HEK 293 cell line will more readily incorporate
and express the BabV3 vaccine with an SXD backbone than the macrophage cell line because of
their ease in culturing and transfecting.
2.2. Aim 1
2.2.1. Material and Methods
2.2.1.1. Cell lines
The Human Embryonic Kidney cell line provided by Louisiana State University (LSU)
AgCenter Biotechnology Laboratory (ABL) Animal Tissue Culture facility. The Ovine Kidney
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cell line was ordered from atcc.org. The ATCC number: CRL-6549, organism: Ovis aries, sheep,
tissue: kidney, disease: none. OA4K/S/Kidney sheep lot number: 58998958.
2.2.2.2. Cell Culture Transfection protocol
Two thousand and five hundred nanograms of the vector containing the Brucella abortus
vaccine 3 epitopes and the CMV PBS Puro backbone (CPPB3) and the vector containing the
Brucella abortus vaccine 4 epitopes and the CMV PBS Puro backbone (CPPB4) DNA were
transfected into each cell line. The concentrations of DNA were determined utilizing a Nanodrop
2000 (ThermoFisher Scientific, Waltham, MA), which is a spectrophotometer used to quantify
and assess the purity of DNA, RNA, and proteins. This concentration was chosen because it is
recommended by the manufacture for 6-well plates on the Lipofectamine 3000 transfection
reagent protocol; however, T-25 flasks were used for transfection for ease of storage and
reproducibility. The concentration of DNA and the amount of transfection reagents were
converted from one well on a 6-well plate to one T-25 flask based on surface area. Cells were
cultured in 5% Fetal Bovine Serum (FBS) in Minimum Essential Medium +Earle’s Salts+ 25mM
HEPES + GlutaMAX media. The cells were transfected with Lipofectamine 3000 using both
22.5 l and 11.25 l of the transfection reagent in separate transfections. Puromycin (InvivoGen,
San Diego, CA) concentrations specific to each cell type (HEK 293 cells: 0.06 μg/mL and ovine
kidney cells: 0.1 μg/mL) were used in the culture media to begin the selection process. Cells not
successfully transfected with the vector are eliminated by the puromycin.
2.2.2.3. Spent media collection
Spent media was collected from flasks in which 50% or ~1.4x106 cells were transfected.
The media was collected in 2 mL tubes and stored in the -30°C freezer for later analysis. Spent
media was collected from control cells as well.
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2.2.2.4. Cell lysate collection for harvesting mRNA
Cells selected in the presence of puromycin were split into T-75 flasks and allowed to
grow to 80-90% confluency (~8.4 X106 cells) to collect cell lysate. An extraction buffer, utilized
to extract cell lysate from the transfected and control cells, was created using PMSF, M-PER
Mammalian Protein Extract Reagent, and Halt Protease and Phosphatase Inhibitor Cocktail
(ThermoFisher Scientific, Waltham, MA). Five microliters of 200mM PMSF was made in
advance, stored at -20°C, and was mixed with 995 μl of 100% ethanol (ETOH) to create 1mL of
the 1mM solution. One milliliter of the 1mM PMSF, 28.7 mL M-Per, and 287 μl of
Phosphatase/protease cocktail were added together to create a complete extraction buffer, with
each component at a 1mM concentration. The T-75 flasks, Dulbecco’s Phosphate-Buffered
Saline (DPBS), 15 mL centrifuge tubes, and 2 mL microcentrifuge tubes were chilled on ice.
Spent media from the T-75 flasks was discarded and the flasks were rinsed with 10 mL of ice
cold DPBS, which was discarded, and 3.75 mL of complete extraction buffer was added to each
flask and allowed to incubate on ice for ~5 minutes. Each flask was scraped using a cell scraper
to remove the adherent cells from the flasks. The mixture of cells and complete extraction buffer
was aspirated into pre-chilled 15 mL centrifuge tubes, vortexed briefly at low speed, and
incubated on ice for ~30 minutes. After incubation, all tubes were centrifuged at 18,928 x g for
10 minutes at 4°C to pellet the insoluble contents. The supernatant was carefully removed and
aliquoted into pre-chilled 2 mL tubes and stored at -80°C. Cell lysate from non-transfected cells
were simultaneously collected for comparison.
2.2.2.5. Harvesting mRNA
Cell lysates were thawed and homogenized in a QIA Shredder spin column, followed by
centrifugation at 13.3 x g for 1 minute. mRNA was harvested from the homogenized cell lysate
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using a RNeasy Plus mini kit (Qiagen, Germantown, MD). The samples were stored at 4°C until
testing.
2.2.2.6. rtPCR for cDNA determination
A reverse transcription PCR (rtPCR) was conducted on the mRNA harvested from HEK
293 and ovine kidney cells transfected with CPPB3/CPPB4. The rtPCR was performed utilizing
a Qiagen OneStep Ahead RT-PCR Kit following the manufacturer’s instructions (Germantown,
MD). Separate rtPCRs were conducted looking for different amplicons; one within the BabV3
vector, one within the BabV4 vector, and two from genes specific to HEK 293 cells: Zinc Finger
Protein 223 (ZNP223) (ZNF223 human Qpcr primer Pair) and Ubiquitin specific peptidase 18
(USP18) (UBP43 (USP18) Human Qpcr primer pair). The two conserved genes were found on
the Maayanlab Harmonize website and the primer sequences were found on the OriGene website
(Harmonizome Integrated Knowledge about Genes & Proteins 2021, OriGene Technologies
2021). Conserved genes for the ovine kidney cells could not be determined utilizing available
resources.
2.2.2.7. Enzyme-linked immunosorbent assay (ELISA)
The 96 well EIA/RIA high binding plates (CoStar, Washington, D.C.) were coated with 5
g/mL of RB51 Brucella Antigen Stationary Phase, 5 g/mL RB51 Brucella Log phase, and the
spent media and cell lysate of HEK 293 and ovine kidney cells transfected with CPPB3 or
CPPB4. The samples were mixed with 1x carbonate buffer (pH 9.6) and incubated overnight at
4°C. Complete coating typically takes 12-18 hours. The two positive controls, RB51 Brucella Ag
Stationary Phase and RB51 Brucella Ag Log Phase, were kindly provided by Dr. Phil Elzer. A
negative control of non-transfected spent media and cell lysate were used.
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Table 2.1. BabV3, BabV4, and Hek 293 house-keeping primer sequences
Primer Name
Primer Sequence
BabV3 cDNA F
5’-TAGTGCCGCAGCCCTCGTGGCAGC-3’
BabV3 cDNA R
5’-CCCGGGACCTATGTCGGCGGCCATG-3’
BabV4 cDNA F
5’-GGGCGGCCTCAAAATCGCCGCTGT-3’
BabV4 cDNA R
5’-CCGCCGTACGCGGACGTGGAGGT-3’
ZNP223 F
5’-TTCAGGAACCTGCTGTCAGTGG-3’
ZNP223 R
5’-GTGGTCCTGCTTCTGGAAAAGTC-3’
USP18 F
5’-TGGACAGACCTGCTGCCTTAAC-3’
USP18 R
5’CTGTCCTGCATCTTCTCCAGCA-3’
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Melting Temperature
69.7°C
69.1°C
69.8°C
69.5°C
59.3°C
58°C
59.3°C
59.1°C

Annealing Temperature
65°C
65°C
65°C
65°C
55°C
55°C
55°C
55°C

The blocking buffer used was a 5% bovine serum albumin (BSA) solution consisting of 40 g
Sucrose+ 10 mL glycerol + 25 g BSA+ 500 mL DPBS.Blocking buffer consisting of a 5% BSA
solution was utilized to improve the sensitivity of the assay by reducing the background
interference. Primary and secondary antibodies were diluted in the 5% BSA blocking buffer as
well. All samples were run in duplicates and a two-fold dilution was performed starting in row A
of a 96 well ELISA plate and working down the columns through H. The samples were diluted
with DPBS and DPBS was also used to serve as a ‘blank’ to test for background or unspecific
binding in some ELISAs. Dilutions ranged from 1:50-1:1600. The primary antibody solution
consisted of blocking buffer and goat anti-RB51 serum from immunized goats and the secondary
antibody solution consisted of blocking buffer and rabbit anti-goat IgG (H+L) HRP
(ThermoFisher Scientific, Frederick, MD). ELISA plates were washed between each step using
the wash buffer consisting of 10XTBS and 20% tween 20. The reaction was visualized by the
addition of 100 l of 1-Step Ultra TMB-ELISA buffer at room temperature and stopped at 15
minutes with 100 l 2M H2SO4. The absorbance was measured on a Benchmark Plus Microplate
Reader (Bio-Rad, Hercules, CA) at 450 nm.
2.2.2.8. Data Analysis
All ELISA data was analyzed with a One-Way ANOVA utilizing the post hoc Tukey test
on GraphPad Prism 9. It was determined that P >0.1 signified that there was no antibody
response, and an antibody response was determined to be P ≤ 0.05.
2.2.2. Results
Using rtPCR it was determined that CPPB3 was present in transfected HEK 293 cells.
Figure 2.1 showed the presence of the BabV3 epitopes in HEK 293 cell samples visualized on an
agarose gel. The lack of bands in lanes 4 and 5 in Figure 2.1 demonstrate that the BabV4

49

epitopes were unable to be detected via this testing method. Specific primers were created to
detect the epitopes from the BabV3 and BabV4 vectors (Table 2.1). In Figure 2.2 primers created
to detect two house-keeping genes within the HEK 293 cell line (Table 2.1) were utilized. The
ability to detect these genes acted as a control to demonstrate the rtPCR kit being utilized worked
correctly. Through ELISA testing it was determined that CPPB3 and CPPB4 were unable to be
detected in both HEK 293 and ovine kidney cells via this testing method. Figures 2.3 and 2.4
show HEK 293 cell samples transfected with CPPB3 and CPPB4 respectively. In both figures
the response from the negative controls consisting of non- transfected samples had higher
absorbances than the transfected samples. This data indicated that there was something in the
controls that was able to cross react and cause a positive response when there should not have
been one. In Figure 2.5 the ovine kidney cells transfected with CPPB3 and CPPB4 were
analyzed and the results were similar to Figures 2.3 and 2.4 in that the response from the nontransfected samples had higher absorbances than the transfected samples.
2.3.AIM 2
2.3.1. Materials and methods
2.3.1.1. Construction of vaccines for animal injections
A double digest on CPPB3 was conducted using the restriction enzymes XhoI and EcoRI
(Fast Digest Enzymes, ThermoFisher Scientific, Waltham, MA). The digest was visualized on a
1% SYBR safe gel to extract the band of DNA containing the CMV promoter, the epitopes
specific to BabV3 and the poly A tail (~2,766 amino acids). A single digest was performed on
the SXD backbone with EcoRI. The digest was then heat inactivated at 80°C for 5 minutes and
treated with Alkaline Phosphatase, Calf Intestinal (CIP) (New England Biolabs, Ipswich, MA) to
remove phosphates from the 5’ and 3’ ends of the DNA.
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1 2 3 4 5
Figure 2.1. Lane 1 is a 1kb ladder for reference. A band corresponding to the expected size PCR product is visible in lanes 2 and 3
which appears to demonstrate that there was cDNA created which suggests a successful transfection of the CPPB3 vaccine in HEK 293
cells. The two rtPCRs from CPPB4 were not evident on the gel (lanes 4 and 5).

1
2
3
4
5
Figure 2.2. Lane 1 is a 100bp ladder, lane 2 is a 1kb ladder, lane 3 is an rtPCR corresponding to primer ZNP223, lane 4 is an rtPCR
corresponding to primer UP18, and lane 5 is a supercoiled ladder. The two bands in lanes 3 and 4 appear to demonstrate that there was
cDNA created in response to the HEK 293 housekeeping genes.
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Figure 2.3. The absorbances of HEK 293 cells both transfected and non-transfected with CPPB3 visualized using an ELISA. The P
value p<0.001 showed that there was a difference in the absorbances of the transfected and non-transfected cell lysates because the nontransfected samples had a higher absorbance than the transfected samples, which indicated that the CPPB3 vaccine was not detectable in
this cell line.
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Figure 2.4. The absorbances of the HEK 293 cells both transfected and non-transfected with CPPB4. The P value p<0.001 showed that
there was a difference between the DBPS controls and the CPPB4 cell lysate because the non-transfected samples had a higher absorbance
than the transfected samples.
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Figure 2.5. The P value p<0.0001 showed there was no reaction on the ELISA from the positive control or the transfected cell lysate.
The minor spike in the non-transfected cell lysate shows that there was a possible cross contamination causing the sample to react. The
absorbances are not significant.

54

The bands corresponding to CPPB3 and the SXD digest were purified utilizing Zymo Clean and
Concentrator Kit (Zymo Research, Irvine, CA) to purify the target DNA. The DNA was eluted in
water for direct use in ligation. The ligation was performed with 5 l of the purified band
extracted from CPPB3 digest and 1 l of the SXD backbone. A Quick Ligase buffer (New
England Biolabs, Ipswich, MA) was utilized, and the mixture was incubated at room temperature
for 20 minutes. Competent E. coli cells were utilized for transfection. The transfection was
performed utilizing CaCl2 competent cells (New England Biolabs, Ipswich, MA C2992) as
follows: CaCl2 competent cells were thawed on ice and 4 l of the BabV3/SXD ligation was
added to a tube containing 50 μl of competent cells. The mixture was incubated on ice for 30
minutes, heat shocked at 42°C in a water bath for 30 seconds, and then incubated on ice for 5
minutes. Next, 950 μl of 25°C SOC media was added and the tube were placed in a shaking
incubator at 37°C for 60 minutes. One hundred microliters of the transfection were spread on ½
super broth plates (BD, Franklin Lakes, NJ) to be grown overnight in an incubator at 37°C. After
20 hours at 37°C, isolated colonies were picked to 1 mL ½ super broth for further screening,
incubated overnight at 37°C, and the vaccine DNA isolated using a ZR mini prep kit (Zymo
Research, Irvine, CA). Agarose gel electrophoresis was used to identify the correct size of the
pDNA, and these samples were further characterized by DNA sequencing to confirm the
sequence was correct and free of base pair mutations.
2.3.1.2. Cell Lines
The Human Embryonic Kidney cell line and J774 cell line were provided by Louisiana
State University (LSU) AgCenter Biotechnology Laboratory (ABL) Animal Tissue Culture
facility.
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2.3.1.3. Lipofectamine 3000 Cell Culture Transfection Protocol-HEK 293
Six T-25 flasks were seeded with approximately 0.7x106 HEK 293 cells which were
dissociated using TrypLE Express Enzyme (ThermoFisher Scientific, Waltham, MA). The T-25
flasks were incubated at 37°C supplemented with 5%CO2 for 48 hours until they were
approximately 50% confluent containing ~1.4x106 cells. A 2.25 mL aliquot of serum-free
Minimum Essential Medium +Earle’s Salts+ 25mM HEPES + GlutaMAX media was added to a
15 mL conical tube supplemented with 67.5 μl of lipofectamine 3000 reagent. This mixture was
vortexed briefly. Then 2.25 mL of serum free media containing 13.5 μl of SDB3 midi prep DNA
(~2.5 μg of DNA/ T-25 flask) and 90 μl of P3000 reagent was added to the mixture followed by
brief vortexing and incubation at room temperature for 15 minutes. Approximately 700 μl of the
transfection complex was added to each of the six T-25 flasks.
2.3.1.4. Electroporation Transfection Protocol HEK 293 and J774
The electroporation system used was a Gene Pulser II (BioRad, Hercules CA) and the
protocol followed was obtained from the BioRad website (Gene Pulser Electroprotocols Species:
Human, 293, kidney cells, Hamster, CHO, ovary cells). In preparation for electroporation, 24
hours prior to the experiment the cells were washed with DBPS and the media was changed to
50:50 Hamms F-12/ DMEM media + 10% FBS. The cells were in log phase prior to
electroporation. On the day of electroporation, the cells were dissociated with TripLE Express
(ThermoFisher Scientific, Waltham, MA). Eight hundred microliters of cell suspension and 2
μg/mL of DNA were loaded into a cuvette with a 0.4 cm gap. Electroporation was performed at
room temperature with the voltage for HEK 293 cells equal to 0.245 kV and equal to 0.2 kV for
the J774 cells. The field strength was set to 0.098 kV/cm, the capacitor was 960 μF, and the time
constant was 10-15 milliseconds for both cell types. The cuvettes were incubated post-pulse for

56

20 minutes at 37°C with 5% CO2. After incubation the cells were placed in T-75 flasks and the
outgrowth media for the HEK 293 cells was 50:50 Hamms F-12/ DMEM media + 10% FBS and
for the J774 cells it was DMEM+ 10% FBS. The T-75 flasks were incubated at 37°C with 5%
CO2 until lysate was collected.
2.3.1.5. Cell Lysate Collection for harvesting mRNA
Flasks were collected for cell lysate at day 2 and day 5 post transfection following the
curve of green fluorescent protein (GFP). There was 1 flask collected for day 2 and 1 flask
collected for day 5 for each cell type per transfection. The extraction buffer was created using
PMSF, M-PER Mammalian Protein Extract Reagent, and Halt Protease and Phosphatase
Inhibitor Cocktail (ThermoFisher Scientific, Waltham, MA). Five microliters of 200 mM PMSF
was mixed with 995 μl of 100% ethanol (ETOH) to create 1 mL of a 1 mM solution. One
milliliter of 1 mM PMSF, 28.7 mL M-Per, and 287 μl of phosphatase/protease cocktail were
combined to create a complete extraction buffer. The T-25/T-75 flasks, Dulbecco’s PhosphateBuffered Saline (DPBS), 15 mL centrifuge tubes, and 2 mL microcentrifuge tubes were chilled
on ice. Spent media from the T-25/T-75 flasks were discarded and the flasks were rinsed with 10
mL of ice cold DPBS, which was discarded before 3.75 mL of complete extraction buffer was
added to each flask and allowed to incubate on ice for ~5 minutes. Each flask was scraped using
a cell scraper to get the confluent cells from the flasks. The mixture of cells and complete
extraction buffer was aspirated into the pre-chilled 15 mL centrifuge tubes, vortexed briefly at
low speed, and incubated on ice for ~30 minutes. After incubation the tubes were centrifuged at
18,928 x g for 10 minutes at 4°C to pellet the insoluble contents. The supernatant was carefully
removed and aliquoted into the pre-chilled 2 mL tubes and the tubes were stored at -80°C. Cell
lysate from non-transfected cells were simultaneously collected for comparison.
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2.3.1.6. Harvesting mRNA
Cell lysates were thawed and homogenized in a QIA Shredder spin column, which was
centrifuged at 13.3 x g for 1 minute. mRNA was harvested from the homogenized cell lysate
using a RNeasy Plus mini kit (Qiagen, Germantown, MD). The samples were stored at 4°C until
testing.
2.3.1.7. rtPCR for cDNA determination
An rtPCR was conducted on the mRNA harvested from HEK 293 and J774 cells
transfected with SDB3 and GFP and non- transfected HEK 293 and J774 cells. The rtPCR was
performed utilizing the Qiagen OneStep Ahead RT-PCR kit following the manufacturer’s
protocol (Germantown, MD). Roughly 20 rtPCRs were run; one within the SDB3 vector, a gene
specific to HEK 293 cells: ZNP223, and two genes specific to J774 cells: Paraoxonase 1 (PON1)
and Low-density lipoprotein receptor-related protein 1 (LRP1). The two conserved genes from
the J774 cells were found on the Maayanlab Harmonize website and the primer sequences were
found on the OriGene website (Harmonizome Integrated Knowledge about Genes & Proteins
2021, OriGene Technologies 2021).
2.3.1.8. Enzyme-linked immunosorbent assay (ELISA)
The 96 well EIA/RIA high binding plates (CoStar, Washington, D.C.) were coated with 5 g/mL
RB51 Brucella Log phase, and the spent media and cell lysate of HEK 293 and J774 cells
transfected with SDB3 and GFP. The samples were mixed with carbonate buffer and incubated
overnight at 4°C. Complete coating typically occurs in 12-18 hours. The positive control was
RB51 Brucella Ag Log Phase, and it was kindly provided by Dr. Phil Elzer. A negative control
of non-transfected spent media and cell lysate were used.
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Table 2.2. Electroporation Data
Cuvette Label
SDB3
SDB3
GFP
GFP
SDB3
SDB3
GFP
GFP

Cell Type
HEK293
HEK293
HEK293
HEK293
J774
J774
J774
J774

Capacitance
(microfarads)

Actual Volts
0.24
0.24
0.24
0.24
0.2
0.2
0.2
0.2

Table 2.3. J774 cell House-Keeping Primer Sequences
Primer Name
Primer Sequence
PON1 F
5’-ATGCTCTCCGAGAGGTACAACC-3’
PON1 R
5’-GCCAGTCCATTAGGCAGTATCTC-3’
LRP1 F
5’-CAACGGCATCTCAGTGGACTAC-3’
LRP1 R
5’TGTTGCTGGACAGAACCACCTC-3’

Table 2.4. GFP House-Keeping Primer Sequences
Primer Name
Primer Sequence
GFP FWD
5’-GGCCTGCCCGCCATGGAGATC-3’
GFP REV
5’-ACCGGCATCTGCATCCGGGG-3’

960
960
960
960
960
960
960
960

Melting Temperature
58.4°C
57.1°C
57.6°C
59.5°C

Melting Temperature
65.5°C
65.2°C
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Time Constant
(milliseconds)
11.4
11.4
10.8
11
12.3
12.3
12.4
12.3

Annealing Temperature
54°C
54°C
54°C
54°C

Annealing Temperature
60°C
60°C

The blocking buffer used was a 5% bovine serum albumin (BSA) solution consisting of 40 g
Sucrose+ 10 mL glycerol + 25 g BSA+ 500 mL DPBS. Blocking buffer consisting of a 5% BSA
solution was utilized to improve the sensitivity of the assay by reducing the background
interference. The primary and secondary antibodies were diluted in 5% BSA blocking buffer as
well. All samples were run in duplicates and a two-fold dilution was performed starting in row A
of a 96 well ELISA plate and working down the column through H. The samples were diluted
with DPBS and DPBS was also used to serve as a ‘blank’ to test for background or nonspecific
binding. Dilutions ranged from 1:50-1:1600. Primary antibody solution consisted of blocking
buffer and goat anti-RB51 serum from immunized goats and the secondary antibody solution
consisted of blocking buffer and rabbit anti-goat IgG (H+L) HRP (ThermoFisher Scientific,
Frederick, MD). The plate was washed between each step using the wash buffer consisting of
10XTBS and 20% tween 20. The reaction was visualized by the addition of 100 l of 1-Step
Ultra TMB-ELISA buffer at room temperature and stopped at 15 minutes with 100 l 2M H2SO4.
The absorbance was measured on a Benchmark Plus Microplate Reader from Bio-Rad (Hercules,
CA) at 450 nm.
2.3.1.9 Data Analysis
All ELISA data was analyzed with a One-Way ANOVA utilizing the post hoc Tukey test
on GraphPad Prism 9. It was determined that P >0.1 signified that there was no antibody
response, and an antibody response was determined to be P ≤ 0.05.
2.3.2. Results
The ELISAs performed during this experiment reacted similarly to the previous cell
culture ELISAs (Figures 2.3, 2.4, 2.5). Figure 2.6 demonstrated that the non-transfected J774
samples had higher absorbance readings than the transfected samples. This data indicated that
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there was cross reaction occurring on the ELISA causing the negative controls to react when they
should not. Figures 2.7 and 2.8 represent the HEK 293 cells transfected via lipofectamine and
electroporation (Table 2.2), respectively. Both ELISAs again demonstrated the non-transfected
samples had higher absorbance readings than the transfected samples. These samples were also
tested using rtPCR with house-keeping genes from J774 cells, HEK 293 cells, and GFP as
controls. Figure 2.9 depicts the J774 cell samples transfected with SDB3 and GFP analyzed with
two house-keeping primer sequences (Table 2.3). This gel demonstrated that the house-keeping
genes could be detected via this testing method regardless of being transfected with different
vectors. Figure 2.10 contains samples of both HEK 293 and J774 cells transfected with the GFP
vector via lipofectamine and electroporation and analyzed utilizing GFP primers (Table 2.4).
This gel served as an additional control for this testing method. In Figure 2.12 the HEK 293 cell
samples were tested using housekeeping primers (Table 2.1). Figure 2.11 illustrates HEK 293
and J774 cells transfected with SDB3 via lipofectamine and electroporation analyzed with
primers specific to the BabV3 epitopes (Table 2.1). In this experiment, it was determined by the
visualization of bands on an agarose gel that the SDB3 vector was successfully transfected
utilizing these cell types and these transfection reagents. Figures 2.9, 2.10, and 2.12 serve as
additional controls for Figure 2.11 by demonstrating the rtPCR kit utilized for these experiments
was working correctly, they demonstrated that there was a sufficient amount of mRNA harvested
in order for the samples to be readily detected via this testing method, and they also acted as
additional controls for the ELISAs by proving the SDB3 vector was able to be successfully
transfected, but not readily detected via an ELISA.
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2.4. Discussion
The HEK 293 cells were utilized to determine expression of the vector in a human cell line,
which is important to note because there are no human rDNA vaccines available at this time.
However, the main way to prevent the spread of brucellosis to humans is through successful
vaccination and eradication in animals. An ovine kidney cell line was chosen because there were
no caprine continuous cell lines readily available at the time of experimentation and the two
species are closely related; therefore, the ovine cell line was chosen as a model of caprine cells
(Mansuroglu et al. 2010). Caprine were utilized in the animal model for the vaccines. The J774
cells are a mouse macrophage line and they served as a model for immune system cells and the
potential ability of the vaccine(s) to be transfected into these cells and expressed. There were two
quantities of Lipofectamine 3000 reagent utilized for transfection to determine which
concentration of Lipofectamine 3000 is optimal for each cell type. As per the manufacturer’s
protocol, there is a high and low amount of the reagent that can be utilized, and to which each
cell type reacts differently. The high dose of Lipofectamine 3000 reagent appeared to be more
successful for this study. A specific amount of puromycin was used for each cell type depending
upon tolerance and the need/ ability for selection; HEK 293 cells received 0.06 μg/mL and the
ovine kidney cells received 0.1 μg/mL. The presence of the puromycin gene in the vector
backbone provided antibiotic resistance to puromycin. Therefore, the puromycin was acting as a
selecting agent by killing cells not successfully transfected with CPPB3/ CPPB4. The J774 cell
line was only transfected with SDB3 which does not contain the puromycin antibiotic resistance
gene; therefore, there was no selection performed in this cell line. Once the transfected cells were
established, the amount of puromycin was slowly tapered off for maintenance instead of further
selection to reduce the risk of propagating antibiotic resistant cells.
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Figure 2.6. The absorbances of the J774 cells both transfected and non-transfected with SDB3 and GFP visualized using an ELISA.
The P value p<0.001 showed that there was a difference in the absorbances of the transfected and non-transfected cell lysates because the
non-transfected samples had a higher absorbance than the transfected samples, which demonstrated that the SDB3 and GFP DNA were not
readily detectable in this cell line.
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Figure 2.7. The absorbances of HEK 293 cells both transfected and non-transfected with SDB3 and GFP visualized using an ELISA.
The P value p<0.001 showed that there was a difference in the absorbances of the transfected and non-transfected cell lysates because the
non-transfected samples had a higher absorbance than the transfected samples, which showed that the SDB3 vaccine and GFP DNA were
not readily detectable in this cell line.
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Figure 2.8. The absorbances of HEK 293 cells both transfected and non-transfected with SDB3 and GFP visualized using an ELISA.
The P value p<0.001 showed that there was a difference in the absorbances of the transfected and non-transfected cell lysates because the
non-transfected samples had a higher absorbance than the transfected samples, which showed that the SDB3 vaccine and GFP DNA were
not readily detectable in this cell line.
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Figure 2.9. Lane 1 is a 1kb ladder and lane 2 is a 100bp ladder. Lane 3 is a control PCR utilizing the LRP1 primers for non-transfected
J774 cells. Lanes 4 and 5 are PCRs utilizing the LRP1 primers for J774 cells transfected with SDB3. Lanes 6 and 7 are PCRs utilizing
the LRP1 primers for J774 cells transfected with GFP. Lane 8 is a control PCR utilizing the PON primers for J774 cells on mRNA
from non-transfected J774 cells. Lanes 9 and 10 are PCRs utilizing the PON primers on J774 cells transfected with SDB3. Lanes 11
and 12 are PCRs utilizing the PON primers on J774 cells transfected with GFP.
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Figure 2.10. Lane 1 is a 1kb ladder and lane 2 is a 100bp ladder. Lane 3 is a control PCR performed utilizing mRNA from nontransfected HEK 293 cells. Lanes 4-7 are PCRs performed utilizing GFP primers on HEK 293 cells transfected with GFP. Lane 8 is a
control PCR performed utilizing mRNA from non-transfected J774 cells. Lanes 9 and 10 are PCRs performed utilizing GFP primers on
J774 cells transfected with GFP.
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Figure 2.11. Lane 1 is a 1kb ladder and lane 2 is a 100bp ladder. Lane 3 is a control PCR performed utilizing mRNA from nontransfected HEK 293 cells. Lanes 4-7 are PCRs performed utilizing BabV3 primers on HEK 293 cells transfected with SDB3.
Lane 8 is a control PCR performed utilizing mRNA from non-transfected J774 cells. Lanes 9 and 10 are PCRs performed
utilizing BabV3 primers on J774 cells transfected with SDB3.
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Figure 2.12. Lane 1 is a 1kb ladder for size reference. Lane 2 is a control PCR performed utilizing mRNA from non-transfected HEK
293 cells with the ZNP223 HEK primers. Lanes 3-6 are PCRs performed utilizing the ZNP223 primer on HEK 293 cells transfected
with SDB3. Lanes 7-10 are PCRs performed utilizing the ZNP223 primers on HEK 293 cells transfected with GFP.
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Once the cell lysate was collected, the QIA Shredder was used to further homogenize the
cells before their use in the RNeasy Plus mini kit. Complementary DNA (cDNA) was
synthesized to determine the amount of mRNA being transcribed within the cells thus
determining whether or not the vector was in the cells and functioning as designed. Through
rtPCR, it was demonstrated that the transfection of HEK 293 cells with CPPB3 was successful
based on Figure 2.1 which showed the size of the PCR product was ~100 base pairs. Primers
specific to a portion of the BabV3 vaccine were used as well as primers corresponding to two
house-keeping genes specific to HEK 293 cells: Zinc Finger Protein 223 (ZNP223) and
Ubiquitin specific peptidase 18 (USP18) (refer to Table 2.1.). These genes were selected as
reaction controls because they are highly conserved in all HEK 293 cell lines. The rtPCR on
CPPB4 in HEK 293 and ovine kidney cells and the rtPCR on CPPB3 in ovine kidney cells were
unsuccessful for several possible reasons. It is possible that the vaccines were not successfully
transfected into the ovine kidney cell line though the change in morphology and the puromycin
selection process indicated otherwise. It is possible that little to none of the vector entered the
ovine kidney cells, due to size or human error. There is also the possibility that there was an
insufficient amount of mRNA harvested for CPPB4 in HEK 293 cells as well which is why there
was no visualization of a band. These potential issues could also play a role in the results of the
ELISAs.
ELISAs were conducted to detect expressed epitope antibodies from convalescent serum.
It was determined that P >0.1 signified that there was no antibody response, and an antibody
response was determined to be P ≤ 0.05. The P value P ≤ 0.001 showed that there was a
difference in the CPPB3 HEK 293 cell ELISA between each concentrated sample and its
unconcentrated counterpart (see Figure 2.3.). The ELISA also showed that there was a difference
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between the cell lysate transfected with the CPPB3 vaccine and the non-transfected HEK 293
cell lysates because the non-transfected samples had a higher absorbance than the transfected
samples. Thus, demonstrating that the epitopes present in the CPPB3 vaccine were not readily
detectable via convalescent serum with this testing method. Likewise, in the ELISA testing the
CPPB4 HEK 293 cells and the ELISA testing both vaccines in the ovine kidney cells, there was a
significant absorbance because the non-transfected samples had a higher absorbance than the
transfected samples, which suggested that the vaccines were not readily detectable via
convalescent serum (see Figures 2.4. and 2.5.). However, in the latter two ELISAs, there was a
spike in the absorbance of the non-transfected cell lysate suggesting human error or the
possibility that there was non-specific cross reaction occurring. It is also possible that an ELISA
may not be sensitive enough for the small amounts of protein to be detected.
When transfecting SDB3, lipofectamine 3000 and electroporation were used. While
electroporation can have a high cell death rate it was utilized here because of the low transfection
efficiency observed by lipofectamine 3000 alone and because of the successful transfections
observed in cells that survive the process. A comparison was conducted to determine the best
transfection method for the rDNA vaccine in these cell lines. The ovine kidney cells were not
utilized in the second half of the experiment due to lack of successful expression in the original
transfections. The timeline for the cell lysate collection for the second cell culture experiment
was based on the curve of GFP in a study in which nine separate transfections with GFP were
performed and observed visually and with flow cytometry to establish the durability of pDNA
transgene expression in mammalian cells. There was noticeable GFP within 4 hours post
transfection. The mean fluorescence of GFP positive cells appeared at day 2 post transfection
and the overall percent of positive GFP cells peaked at day 5 post transfection. After day 5 the
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amount of fluorescence begins to diminish and by 12-14 days post transfection the GFP reached
baseline levels (Gubin et al. 1999). The second cell culture experiment was based on this
observation and the flaks were collected for cell lysate at day 2 and 5 post-transfection.
The second experiment also utilized electroporation as one of the transfection methods. It
has been shown in a study done by Wang et al. that electroporation could cause integration of
pDNA into genomic DNA following injection in vivo (Wang et al. 2004). Electroporation was
found to increase the level of pDNA associated with high molecular weight genomic DNA.
Integration can be a positive or negative outcome. It has been discussed previously why the
integration of this rDNA vaccine could be negative due to the antibiotic resistance genes present
in the vector backbone. However, integration could be useful for gene therapy when targeting
proliferating cells that would lose episomal plasmids. Electroporation has been shown to increase
transgene expression and could significantly reduce the amount of plasmid needed to protect an
animal. In a study utilizing mice, a 3 g dose of pDNA paired with electroporation resulted in
higher plasmid levels in muscle than a dose of 50 g of plasmid given intramuscularly (IM)
without electroporation. This is approximately a 6-to-34-fold increase in the level of pDNA in
the muscle, which demonstrated that electroporation increases the level of pDNA within the
body.
ELISAs were conducted to detect expressed epitope antibodies. It was determined that
P>0.1 signified that there was no antibody response, and an antibody response was determined to
be P ≤ 0.05. The ELISA containing samples for the HEK 293 lipofectamine 3000 transfection
(see Figure 2.7.) showed that while there was a reaction from the cell lysate collected from SDB3
day 2 and GFP collected day 5, they were not significant despite having an absorbance similar to
the positive control. The DBPS negative control had a higher absorbance than any of the
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transfected samples tested. The non-transfected spent media from HEK 293 cells had an
absorbance similar too/ higher than all samples of spent media throughout the project. Upon
analyzing the ELISAs for the electroporation transfections in HEK 293 (see Figure 2.8.) and
J774 cells (see Figure 2.6.), the results appear similar to the lipofectamine 3000 transfection. The
spent media absorbances measured by the ELISA for both HEK 293 and J774 cells after
electroporation was higher than/ equal to the non-transfected spent media showing that this
method of testing does not yield reliable results. The cell lysate for both SDB3 and GFP on day 2
and 5 had a higher absorbance than the spent media but the absorbances were similar to the
DPBS and non-transfected cell lysates. This demonstrates that the epitopes from SDB3 were not
expressed or readily detectable via convalescent serum with this testing method. The ELISA
sensitivity and transfection methods may need to be further evaluated to determine whether the
inability to detect a plasmid of this size is due to human error in testing or the plasmid itself.
Roughly 20 or more rtPCRs were conducted to determine successful transfection of the
HEK 293 and J774 cells with SDB3 and GFP. The housekeeping gene rtPCRs were designed to
serve as a control. The LRP1 and PON primers for the J774 cells created amplicons that were
~100-150 base pairs thus demonstrating that the housekeeping genes in J774 cells were able to
be readily detected using rtPCR (see Figure 2.9.). The ZNP223 primers for HEK 293 cells
showed bands ~100-150 base pairs for all samples including the control non-transfected HEK
293 cells, which showed that the housekeeping gene can be readily detected through this method
of testing as well (see Figure 2.12.).
The rtPCRs performed utilizing the GFP primers served as an additional control. The
rtPCRs performed on cells transfected with GFP displayed an amplicon that was the correct size
while the non-transfected HEK 293 and J774 cells was not detectable on the agarose gel (see
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Figure 2.10.). The rtPCRs containing the SDB3 mRNA displayed a band ~100 base pairs for all
transfected samples when utilizing the primers specific for the epitopes of BabV3 (see Figure
2.11). These rtPCRs show that while the SDB3 and GFP pDNA was unable to be detected via
ELISA, it was more readily detected through rtPCR. This suggests that the cells were able to be
successfully transfected with this size plasmid but that the plasmid was not being readily
expressed by the cell. However, at the time of initial testing the second cell culture experiment
had not been performed and with the positive result from the rtPCR performed on CPPB3, this
vaccine was carried into further testing utilizing an animal model. Overall, the HEK 293 and
J774 cells performed about the same, while there was no success with the ovine kidney cells
utilizing these testing and transfection methods.
There are several possible reasons overall why the BabV3 and BabV4 epitopes were
unable to be readily detected through these testing methods. It is possible that there was an
insufficient amount of mRNA being translated by the cells and the small amount that was
translated was too low in concentration to be easily detected. Also, the epitopes that were chosen
for the BabV3 and BabV4 vaccines were chosen from the literature because they have been
shown in previous studies to be immunodominant and elicit an immune response in an animal.
However, in these studies the entire epitope was utilized and for this project only portions of the
epitopes were used. The reduction in size of the epitopes may mean that the antigen coating the
ELISAs is unable to detect the portion of the epitopes chosen. Likewise, the primary antibody
may also not be able to readily detect the portions of the epitopes chosen. The vaccines were
designed utilizing portions of the epitopes opposed to the entire epitope in order to create an
immune response to multiple Brucella proteins known to be immunogenic.
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Chapter 3. Animal Model for Brucella Recombinant DNA Vaccines
Aim1: To determine whether CPPB3 or CPPB4 will give a better immune response determined
through antibody detection.
Aim2: To develop an efficient ELISA for testing antibody titers in goats vaccinated with a rDNA
vaccine.
3.1. Introduction
The recombinant DNA vaccines tested were originally designed with epitopes from B.
abortus and codon optimized to the bovine species, but because of the genomic similarities
between Brucella species, it can be theorized there is the potential for protection from brucellosis
infection among varying species, especially from B. melitensis. Due to this similarity among
species of Brucella, a goat model was chosen for testing the Brucella abortus vaccine 3 epitopes
and the CMV PBS Puro backbone (CPPB3) and the vector containing the Brucella abortus
vaccine 4 epitopes and the CMV PBS Puro backbone (CPPB4). Caprine is also the secondary
host for B. abortus, potentially making them a good model for this experiment (Wareth et al.
2015). Any breed of goat could be used for the trials, except for myotonic goats. Myotonic goats
were excluded because they are easily affected by stress, which would contribute to
environmental variables that compromise the goat’s immune systems.
Goats inoculated with a virulent strain of B. abortus develop clinical signs and serological
responses like cattle (Anderson et al. 1986). A caprine model for the study of ruminant
brucellosis is well documented (Anderson et al. 1986; Meador and Deyoe 1986). In a study done
by Meador and Deyoe, pregnant goats were exposed to B. abortus to evaluate their
appropriateness as an animal model for bovine brucellosis. Six of the 10 infected does delivered
dead fetuses, which contained brucellae in multiple tissues, and 1 of the 10 delivered live,
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premature twins. Post parturition, B. abortus was discovered in the milk and uterine fluids of the
infected does (Meador and Deyoe 1986). As a natural host and a ruminant, goats offer many
advantages for brucella studies including that small ruminants cost less than large ruminants;
small ruminants require less space (numbers can be increased for statistical significance); small
ruminants have shorter gestation times, and results can be obtained in a timely manner (Elzer et
al. 2002). It is hypothesized that the goats injected with the CPPB3 vaccine will mount an
immune response more readily than the goats injected with the CPPB4.
3.2. Material and Methods
3.2.1. Acquiring of and initial health check on goats
Twelve domestic meat goats were purchased from Weaver Farms (Sebastopol, MS) and were
housed at the ALAC accredited Reproductive Biology Center (RBC) in accordance with the
Institutional Animal Care and Use Committee (IACUC) protocol number A2018-16. The
animals were quarantined for 30 days prior to the initiation of the trial.
3.2.2. Brucella Card Test
Blood samples were collected from the goats upon arrival to determine a baseline for their
health. Thirty microliters of serum from each goat were placed at the lower half of the “tear
drop” on the Brucella Card Test. Each sample was placed in its own individual “tear drop” for
testing. Thirty microliters of the antigen provided with the test was placed in each tear drop,
away from the sample. The antigen and serum sample were then mixed individually with a clean
wooden stirrer spreading the sample throughout the tear drop shape. After each sample was
mixed, the entire card was gently rocked back and forth for 4 minutes to allow for the mixture to
flow into the apex so that the serum and antigen were in close proximity and then spread out as it
flows away allowing for proper mixing. Agglutination occurs if the sample is positive. A positive
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control of serum from a Brucella infected cow was used and the negative control was serum
from a person known to be brucellosis free (Alton et al. 1988).
3.2.3. Treatment groups
Six goats were assigned to different treatment groups including each vaccine and two control
animals. One control goat received sterile DPBS, one control goat received just the transfection
reagent being utilized in the experimental goats, and 2 goats received each of the two vaccines,
for three groups of two goats each. The dosage was 100 g for all treatment groups in a 1mL
injection with a half milliliter injection on either side of the neck. Subcutaneous vaccines were
delivered behind the neck when the animals reached breeding age, as determined either by
weight or age of 5 to 9 months. Blood was drawn prior to injection and every 6 weeks prior for
36 weeks. The statistical design was a Completely Randomized Design with Repeated Measures.
3.2.4. Preparation of the vaccines used for injection
Each vaccine was prepared in an individual microcentrifuge tube for a total of 4 vaccines.
One hundred micrograms of CPPB3 or CPPB4 midi prep was mixed with 300 l Superfect
transfection reagent (Qiagen, Germantown, MD). Each vaccine has sterile DPBS added, in
varying amounts, for each injection to be adjusted to 1 mL injection volume for consistency
between injections. The vaccines were prepared immediately prior to use in a BSL2 safety
cabinet at RBC where the goats are being housed; vaccines had to be used within 30 minutes of
preparation.
3.2.5. Processing blood samples
Samples were collected using a 20-gauge needle and a BD vacutainer blood collection tube
(BD, Franklin Lakes, NJ). The tubes were allowed to clot overnight at 4°C and then spun down
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in the centrifuge at 2200 x g for 20 minutes. The serum was harvested, aliquoted, and stored at 20°C until testing.
3.2.6. Sample preparation for coating ELISA plates
Freeze dried RB51 Brucella Antigen harvested in Stationary Phase was reconstituted in
DPBS at a concentration of 378 μg/μl, then diluted with DPBS (ThermoFisher, Waltham, MA) to
varying concentrations to optimize results. The final concentration used for testing was
determined to be 5 g/mL.
3.2.7. ELISA procedure
The 96 well EIA/RIA high binding plates (CoStar,Washington, D.C.) were coated with 5
g/mL of RB51 Brucella Antigen Stationary Phase and 1X carbonate buffer (pH 9.6) overnight
at 4°C. Complete coating typically takes between 12-18 hours. The blocking buffer used was a
5% bovine serum albumin (BSA) solution consisting of 40 g Sucrose+ 10 mL glycerol + 25 g
BSA+ 500 mL PBS. The primary and secondary antibodies were diluted in the 5%BSA blocking
buffer as well. There was a negative control consisting of 4 wells on the plate that did not receive
primary antibody but did receive secondary antibody. A positive control of sera from a cow
vaccinated with RB51 was used and it was kindly provided by Dr. Steven Olsen from the USDA
Infectious Bacterial Diseases of Livestock (Ames, IA). Both vaccines were designed without the
lipopolysaccharide (LPS) which is present in the smooth strain of Brucella. This is similar to the
live-attenuated vaccine, RB51, which is also lacking LSP. The positive control was set up in a 6point serial dilution starting at a 1:50 dilution and ending at 1:1600. The primary antibodies were
the sample goat sera diluted with the blocking buffer at a 1:1600 dilution. All samples were run
in duplicates and the plate was washed between each step using the wash buffer consisting of
10XTBS and 20% tween 20. There were two secondary antibodies utilized on each ELISA:
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Rabbit anti Goat IgG (H+L) HRP and Rabbit anti Bovine IgG (H+L) HRP (ThermoFisher
Scientific, Waltham, MA). The bovine secondary antibody was used as a positive control and
two negative control wells while the goat secondary antibody was used for all goat samples and
two negative control wells and this was done to compensate for background or non-specific
binding on the plate. A reaction was visualized by the addition of 100 l of 1-Step Ultra TMBELISA buffer at room temperature and stopped at 2 minutes with 100 l 2M H2SO4. The
absorbance was measured on a Benchmark Plus Microplate Reader from Bio-Rad (Hercules,
CA) at 450 nm.
3.2.8. Data Analysis
Data was analyzed using a one-way analysis of variance (ANOVA) with repeated measures
and a post hoc Dunnett’s multiple comparisons test utilizing the program GraphPad Prism 9.
Values were normalized against sera taken from bovine vaccinated with RB51 to accurately
compare data between ELISA plates. The sera from bovine vaccinated with RB51 was used as a
six-point standard curve on each ELISA performed and was analyzed using nonlinear regression
(x=EC50((bottom-top)/Y-top)-1) ^(1/hillslope). Effects of the vaccine on the animals were
analyzed.
3.3. Results
The animals were assigned to their experimental groups randomly (Table 3.1) and the
experiment was set up as a completely random design with repeated measures. Control goat
#0730 showed a positive result on the Brucella Card test, but all other goats were negative. After
a treatment for a Yersinia infection, goat #0730 tested negative when retested. A standard curve
(Figure 3.1) was utilized in ELISA testing, and it was analyzed using nonlinear regression to
demonstrate absorbance rate at different concentrations of RB51 antibodies present in serum
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from a cow vaccinated against RB51. It was determined that P >0.1 signified that there was no
antibody response. An antibody response was determined to be P ≤ 0.05. Of the two groups of
treatment goats (100 g injection of CPPB3 and 100 g injection of CPPB4) none of the animals
showed any antibody response over time. Figure 3.2 represents the averaged immune response
from the animals over the course of the experiment. There is little to no antibody titer detected
throughout the experiment except for goat 1858, which was part of the CPPB4 experimental
group. This spike may demonstrate the animal’s ability to mount an immune response once
cleared of the extreme parasite load. However, the data (Table 3.2) does show that there was no
significant antibody titer detected throughout this experiment.
3.4 Discussion
The Brucella Card Test was performed on the serum collected from each of the goats to
determine if any of them were infected with Brucella or something that would cross react on an
ELISA such as Yersinia enterocolitica O:9. Control goat #0730 did give a positive result on the
Brucella Card test initially and was treated for a Yersinia infection. Yersinia enterocolitica O:9
and Brucella have the same o- polysaccharide LPS and stress could have caused goat #0730 to
react on the first card test by straining the immune system and exacerbating the existing
infection. Once the infection cleared, goat #0730 was retested and no longer reacted on the card
test. Agglutination tests are used to detect antibodies or antigens and they involve the
agglutination or clumping of bacteria to show a positive reaction. A subcutaneous injection was
given into the fat layer between the skin and the muscle. This type of injection is a favored
method for delivering a drug to get the desired effects quickly and directly.

80

Table 3.1. Pilot Study Experimental Groups
Goat ID Numbers

Experimental Group

0730

DBPS Control

1854

SuperFect transfection reagent Control

1856

CPPB4

1858

CPPB4

1854

CPPB3

1857

CPPB3

Figure 3.1. The standard curve was analyzed using nonlinear regression and shows the absorbance rate at different concentrations of
RB51 antibodies present in cow sera vaccinated against RB51.
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Figure 3.2. Mean concentration of antibodies in samples obtained over approximately an eight-month period from goats treated with a
1mL injection of either the rDNA vaccine CPPB3 or CPPB4. With an average adjusted P value of p=0.85 there was no difference
between the samples taken prior to treatment (pre bleed) and the subsequent samples.
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Table 3.2. Serum Sample Comparisons between Pre-Injection Samples and Post-Injection Samples
Dunnett's Multiple Comparisons Test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 4 weeks

-0.02761 to 0.06686

0.5124

Pre-Bleed vs. 10 weeks

-0.04611 to 0.07092

0.9112

Pre-Bleed vs. 16 weeks

-0.07527 to 0.1129

0.9279

Pre-Bleed vs. 22 weeks

-0.06853 to 0.1183

0.8173

Pre-Bleed vs. 27 weeks

-0.1280 to 0.1574

0.9960

Pre-Bleed vs. Terminal Bleed

-0.6569 to 0.4564

0.9515
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Subcutaneous tissue has few blood vessels, so the injected drug is diffused slowly and at a
sustained rate of absorption, which makes them highly effective for vaccines and insulin among
other prospects (Kim et al. 2017). In addition, subcutaneous injections were utilized because in a
meta-analysis it was determined that when vaccinating against Brucella with the vaccines on the
market, they are given via subcutaneous injection (Dorneles et al. 2021). Subcutaneous injections
do have their limitations, however, including the variation in absorption and action of the drug
from patient to patient. A patient can also experience differing effects of the same drug with
multiple subcutaneous injections, which is why a single injection is being used to reduce the
variation between multiple injections (Kim et al. 2017). Subcutaneous injections were chosen
because that is industry standard for Brucella vaccines.
The Superfect transfection reagent was utilized to complex DNA for vaccinating the
goats. This reagent is used for the transfection of a broad range of eukaryotic cell lines with
DNA, but it is an in vitro transfection reagent not an in vivo transfection reagent. There are
previous studies conducted in our lab showing that it has been used in vivo in poultry and gave
promising results. It was chosen based on this and because it was the most readily available and
cost-efficient option considering the amount required to inject the number of animals needed in
this and future experiments.
Samples were taken from the goats every 6 weeks from the date of vaccination in
November through April and the terminal bleed was performed in July. The gap in sample
collection is due to the poor health of the goats and the need for treatment to eliminate the
extreme parasite infections. The added stress of taking samples would exacerbate the infection
which could influence the potential antibody response within the animal. This period was used to
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give the animals time to recover, but unfortunately after 2 months it was determined that the
animals were not recovering, and a terminal bleed was performed.
A 7-year review of clinical cases at Auburn University Veterinary Medical Teaching
Hospital in Alabama demonstrated that parasitic infection was the primary reason that 70% of
sheep and 91% of goats were examined and treated (Kapla 2004). In a similar study, abomasal or
intestinal worm infection was identified as the predominant disease condition on 74% of sheep
farms. Haemonchus contortus, a blood sucking parasite that thrives in warm climates, is
recognized as the most important pathogen and is found on majority of sheep and goat farms in
the southern US. Infection with H. contortus may cause anemia, loss of condition, reduced
productivity, and eventually death if the infection is severe. Because of warm, humid conditions
during the summer months in southern states, gastrointestinal parasites are the greatest health
concern for goats (Marshall et al. 2017).
Upon analysis of the sera samples collected throughout the study it was determined that
within the DPBS control group (n=1), the SuperFect control group (n=1), and both experimental
groups (n=2) there was no detectable response to the vaccine via antibodies being made. The
confidence intervals show that if the experiment were to be repeated with the same parameters
there would likely still be no difference between the control groups and the treatment groups.
There is no difference between the control groups and the experimental groups with the
exception of goat 1858, which was injected with CPPB4 (Figure 3.2). This animal had a spike in
antibody response at the time of the terminal bleed which was approximately 8 months postvaccination and this animal had not shown any signs of antibody response prior to the terminal
bleed. This spike could be due to several reasons such as error in testing or potential cross
reactivity on the ELISA. There is also the possibility that due to the severe parasite load the
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animals were suffering from the immune system was suppressed and unable to correctly respond
to the vaccines. Goat 1858 may have had a decreased parasite load at the time of the terminal
bleed due to the intensified treatment and this allowed the immune system to response to the
vaccine. Further testing will be required in an environment that can be more readily controlled.
There are several possible reasons overall why the BabV3 and BabV4 epitopes were
unable to be detected through the ELISAs performed. The epitopes that were chosen for the
BabV3 and BabV4 vaccines were chosen from the literature because they have been shown in
previous studies to be immunodominant and elicit an immune response in an animal. However,
in these studies the entire epitope was utilized and for this project only portions of the epitopes
were used. The reduction in size of the epitopes may mean that the antigen coating the ELISAs is
unable to detect the portion of the epitopes chosen. Likewise, the primary antibody may also not
be able to readily detect the portions of the epitopes chosen. The vaccines were designed
utilizing portions of the epitopes opposed to the entire epitope in order to create an immune
response to multiple Brucella proteins known to be immunogenic. Acquiring antibodies specific
to the epitopes from the proteins utilized in the vaccines would have created a more specific
testing method and potentially given more reliable results.
CPPB3 was used for further testing and not CPPB4, despite goat 1858 having a spike at
the terminal bleed, because at the time of the original testing we were working with what was
believed to be an optimized ELISA (based on assistance from someone experienced in ELISA
set up and analysis) and the data from these ELISAs suggested that CPPB3 was causing the
animals to have an immune response. With the results from this ELISA paired with having few
animals in this study it was suggested that the CPPB3 vaccine would need to be tested further in
a larger study to determine if the results were significant. However, when the date was analyzed
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by a statistician, it was determined that the standard curve was incorrect, and the ELISA required
additional optimization. Upon optimization of the ELISA and re-running the samples it was
determined that the only spike was from a goat vaccinated with CPPB4, but there was no
significance in the antibody response from any of the other animals. However, two large scale
experiments were already under way utilizing the BabV3 epitopes.
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Chapter 4. Testing Dosage and Adjuvant Effect on SDB3 in Wethers
Aim1: To determine which combination of vaccine dose and adjuvant shows the greatest
antibody response within the animals.
4.1. Introduction
Upon analyzing the results from the initial animal trial, it was decided that only BabV3
and not BabV4 was used in the subsequent animal trials. In this study BabV3 with an SXD
backbone (SDB3) was used instead of CPPB3 to determine if a reduction in size (from 8,299
base pairs to 7,333 base pairs) of the vector being injected will play a role in the creation of an
antibody response. It has been suggested that the size of the vector is inversely related to the
transfection efficiency; however, some studies do show that a reduction in transfection efficiency
was caused by cytotoxicity associated with the plasmid, not the plasmid size (Cherng et al.
1996). Also, in this study the potential effect of an adjuvant paired with the vaccine was
compared. An adjuvant is an agent that increases specific immune responses to antigens and
good adjuvants should elicit both primary responses and memory T and B lymphocytes.
Adjuvants elicit protective immune responses from bacterial toxoids, viruses, and subunit
antigens produced by rDNA technology (Allison and Byars 1986). The first cell type adjuvants
interact with are macrophages, but T-lymphocytes are also required for the adjuvant’s effect on
antibody formation (Allison and Davies 1971). The surface antigens produced by rDNA vaccines
can elicit protective immune responses, but only when administered with an adjuvant. Adjuvants
utilized in veterinary medicine do have the potential to stimulate undesirable side effects such as
inflammation or pain at the injection site.
The adjuvant utilized was ‘Sterile Diluent Adjuvant’ and came paired with the vaccine
for Bovine Rhinotracheitis-Virus Diarrhea- Parainfluenza 3- Respiratory Syncytial Virus
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Vaccine. Per the manufacture’s instruction the freeze-dried vaccine was to be reconstituted in the
sterile diluent, but for the purposes of this experiment it was given as a separate injection paired
with the SDB3 rDNA vaccine at the suggestion of our collaborator, Dr. R. Keen. The adjuvant
was derived from shark liver oil and oil adjuvants are also commonly known as emulsion
adjuvants and they were first reported in 1916 by Le moini and Pinoy. Jules Freund developed
Freund’s complete adjuvant (FCA) which is a mineral oil-based water-in-oil (W/O) emulsion
(Dalsgaard et al. 1990). In W/O emulsions, water droplets are dispersed in oil, but the results of
this emulsion are dependent upon the volume fraction of both the water and oil and the
emulsifier being utilized. Freund’s adjuvant is one of the most used adjuvants in vaccine research
because of the noticeable effects of emulsions as carriers of vaccine protein and immune
stimulatory molecules (Aucouturier 2001). W/O emulsions typically stimulate high and longlasting immune responses because of the slow release of the antigen and are widely used in
veterinary vaccines. Oil adjuvants can induce MHC and potentially allow the reduction of the
vaccine dose or the antigen concentration while also enhancing the cellular immune response.
Many studies suggest that W/O emulsions induce higher IgG2a antibody levels than other
emulsion types and a squalene-based adjuvant (MF59) has been shown to stimulate both cellular
and humoral immune responses, Th1 and Th2 respectively. Oil- based adjuvants increase
humoral responses of farm animals when paired with many different inactivated bacterial and
viral vaccines (Allison and Byars 1986). Emulsions can protect the antigen from being rapidly
degraded by enzymes and potentially modify the ionic charge of the antigen allowing it to
become more immunogenic by creating inflammation that stimulates the recruitment of APCs.
The uptake by APCs can be explained by the interactions of the surfactant and the cellular
membrane. Oil based adjuvants stimulate the accumulation of lymphocytes in draining lymph
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nodes, called lymphocyte trapping, which alters recirculation and facilitates cell association. One
of the principal modes of action of adjuvants is that they can induce the production of
lymphocyte growth factors by accessory cells (Allison and Byars 1986). Specific cytokines can
also be induced depending upon the type of emulsion used.
In a study comparing different adjuvants and how they affect quantity, affinity, and
concentration of murine antibodies, it was determined that adjuvants can independently enhance
different qualities of antibody responses (Kenney et al. 1989). Meaning that antibody
concentration and affinity are independently related as are isotype and epitope specificity thus
making it difficult to predict the outcome of pairing a specific adjuvant with a new vaccine.
There is also a debate on whether oil-based or non-oily adjuvants offer the greatest protection but
based on a study performed by Puentes et al. the species being vaccinated plays a role in which
will offer greater protection (Puentes et al. 1993). Oily adjuvants (mineral oil) are commonly
used in veterinary medicine. Mineral oil emulsions, which are considered a vehicle, provide large
surface areas which allow the antigen to be retained in a two-dimensional matrix allowing for
easy transfer to APCs (Allison and Byars 1986). In a study done by Dante and other, comparing
oily and non-oily adjuvants mice and swine were tested and when purified glycoproteins were
used as antigens, the use of immunostimulating complex (ISCOM) greatly enhanced specific Tcell responses and protection in mice. ISCOM is a particle containing several copies of an
antigen with a built-in adjuvant that is designed for optimal presentation of the antigen to the
immune system. However, when an ISCOM containing glycoproteins were studied in swine, it
offered no improvement on protection offered by the oily adjuvant but offered greater protection
when administered in mineral oil. The adjuvant that offered the most protection in mice was
saponin, which is a natural glycoside of steroid or triterpene which are widely found in plants
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and is a non-oily adjuvant option. Saponin adjuvants are strong adjuvants because of their ability
to induce cytokine production and the potential to induce Th1 or Th2 depending on their
oligosaccharides (Dante 2018).
However, the precise mode of action of oil-based adjuvants is still unclear (Aucouturier
2001) and while adjuvants are beneficial, they do have the possibility of undesirable side effects.
The first being tissue damage or the production of acute or chronic inflammation at the injection
site (Allison and Byars1986). Granulomas have been shown to be caused by FCA, which is why
they are not approved for use in human medicine or for use in domestic and farm animals. Some
adjuvants do have the ability to produce a fever in the recipient or induce arthritis and anterior
uveitis, which is inflammation of the middle layer of the eye. Despite the potential for negative
side effects, adjuvants have been shown to significantly increase the protection of a vaccine
when utilized correctly. It is thought that the higher dose of the vaccine coupled with an adjuvant
will show the highest antibody response.
4.2. Materials and Method
4.2.1. Acquiring of and initial health check on wethers
Twenty-five domestic meat goats were acquired from a collection of farms in West Texas
and were cared for in accordance with an approved IACUC protocol number A2018-16. The
animals were quarantined for 30 days prior to initiation of the trial.
4.2.2. Brucella Card Test
Blood samples were collected from the goats upon arrival to determine a baseline for
their health. Thirty microliters of serum from each goat was placed at the lower half of the “tear
drop” on the Brucella Card Test. Each sample was placed in its own individual “tear drop” for
testing. Thirty microliters of the antigen provided with the test was placed in each tear drop,
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away from the sample. The antigen and serum sample were then mixed individually with a clean
wooden stirrer spreading sample throughout the tear drop shape. After each sample was mixed,
the entire card was gently rocked back and forth for 4 minutes which allows for the mixture to
flow into the apex so that the serum and antigen are in proximity and then spread out as it flows
away to allow proper mixing. Agglutination will occur if the sample is positive. A positive
control of serum from a Brucella infected cow was used and the negative control was serum
from a person known to be brucellosis free. All the wethers tested negative on the Brucella Card
Test (Alton et al. 1988).
4.2.3. Experimental groups
The goats were randomly assigned to different treatment groups. All injections were
given subcutaneously on the right side of the neck. All wethers were monitored after injection for
any sign of negative reaction including but not limited to swelling or pain at the injection site.
4.2.4. Creation of the vaccine for injection
Each dose of the vaccine was aliquoted to its own tube. For the 100 g injection each
amount of DNA was mixed with 300 l of SuperFect (Qiagen, Germantown, MD) and Q.S.ed to
1mL with sterile DPBS. The SDB3 DNA was added to the tube first followed by the DPBS. The
tube was inverted 5 times to mix thoroughly and then the SuperFect was added and mixed by
pipetting. After a 5-minute incubation at room temperature the vaccine was loaded into a 3 mL
syringe with a Luer-Lok tip for injection (BD, Franklin Lakes, NJ). To create the 200 g
injection, the DNA was mixed with 600 l SuperFect and Q.S.ed to 1 mL with sterile DPBS. The
SDB3 DNA was added to the tube first followed by the SuperFect and mixed by pipetting. The
DPBS was added and following a 5-minute incubation at room temperature the vaccine was
loaded into a syringe.
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Table 4.1. Experimental Groups Containing Wethers
Goat ID Number
1903
1920
1911
1906
1914
1913
1921
1904
1916
1918
1919
1905
1907
1917
1915
1912
1925
1924
1909
1902
1908
1901
1922
1923
1910

Experimental group
DPBS Control
DPBS Control
DPBS Control
DPBS Control
DPBS Control
200g injection+ 200l of adjuvant
200g injection+ 200l of adjuvant
200g injection+ 200l of adjuvant
200g injection+ 200l of adjuvant
200g injection+ 200l of adjuvant
200g injection
200g injection
200g injection
200g injection
200g injection
100g injection + 100l of adjuvant
100g injection + 100l of adjuvant
100g injection + 100l of adjuvant
100g injection + 100l of adjuvant
100g injection + 100l of adjuvant
100g injection
100g injection
100g injection
100g injection
100g injection
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4.2.5. Processing Blood Samples
Samples were collected using a 20-gauge needle and a BD vacutainer blood collection
tube (BD, Franklin Lakes, NJ). The tubes were allowed to clot overnight at 4°C and then
centrifuged at 2200 x g for 20 minutes. The serum was harvested, aliquoted, and stored in the 20°C freezer until needed for testing.
4.2.6. ELISA procedure
The 96 well EIA/RIA high binding plates (CoStar,Washington, D.C.) were coated with 5
g/mL of RB51 Brucella Antigen Stationary Phase and carbonate buffer overnight at 4°C.
Complete coating typically requires 12-18 hours. The blocking buffer used was a 5% bovine
serum albumin (BSA) solution consisting of 40 g Sucrose+ 10 mL glycerol + 25 g BSA+ 500
mL PBS. The primary and secondary antibodies were also diluted in the 5%BSA blocking buffer
as well. A negative control consisted of 4 wells on the plate that did not receive primary antibody
but did receive secondary antibody. The positive control was sera from a cow vaccinated with
RB51. The positive control was set up in a 6-point serial dilution starting at a 1:50 dilution and
ending at 1:1600. The primary antibodies were the sample goat sera diluted with the blocking
buffer at a 1:1600 dilution. All samples were assayed in duplicate. There were two secondary
antibodies utilized on each ELISA: Rabbit anti Goat IgG (H+L) HRP and Rabbit anti Bovine
IgG (H+L) HRP. The bovine secondary antibody was used for the positive control and two
negative control wells. The goat secondary antibody was used for all goat samples and two
negative control wells. This was done to account for any background or non-specific binding on
the plate. The reaction was visualized by the addition of 100 l of 1-Step Ultra TMB-ELISA
buffer at room temperature and stopped at 2 minutes with 100 l 2M H2SO4.
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The absorbance was measured on a Benchmark Plus Microplate Reader from Bio-Rad (Hercules,
CA) at 450 nm. The plate was washed between each step using the wash buffer consisting of
10XTBS and 20% tween 20.
4.2.7. Data Analysis
Data was analyzed using a one-way analysis of variance (ANOVA) with repeated
measures and a post hoc Dunnett’s multiple comparisons test utilizing the program GraphPad
Prism 9. Values were normalized against sera taken from bovine vaccinated with RB51 and used
as a six-point standard curve on each ELISA performed. The standard curve was analyzed using
nonlinear regression (x=EC50((bottom-top)/Y-top)-1) ^(1/hillslope). Effects of the vaccine on
the animals and the potential adjuvant interaction were analyzed.
4.3. Results
The animals were randomly assigned to the experimental groups (Table 4.1) and the
experiment was set up as a completely random design with repeated measures. A total of eight
wethers were lost throughout the course of the experiment (Table 4.7), however, this did not
affect the outcome of the experiment because the deaths were not due to the experimental
vaccine. A standard curve (Figure 4.1) was utilized in ELISA testing, and it was analyzed using
nonlinear regression to demonstrate absorbance rate at different concentrations of RB51
antibodies present in serum from a cow vaccinated against RB51. It was determined that P >0.1
signified that there was no antibody response and/or no effect by the adjuvant. An antibody
response was determined to be P ≤ 0.05. Of the 4 groups of treatment goats (100 g injection,
100 g injection+ adjuvant, 200 g injection, and 200 g injection+ adjuvant) none of the
animals showed an antibody response over time. In Figure 4.2 there are two spikes in antibody
titer, however, this was the control group which indicated that the spike in antibody titer was not
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due to a response from the vaccine and it was determined that there was no antibody response
(Table 4.2). Figure 4.3 depicts the 100g experimental group in which there were two spikes in
antibody concertation, however, (Table 4.3) there was no significant antibody response over the
course of the experiment. Figure 4.4 indicated similar results in that there was no detectable
antibody response and based on analysis (Table 4.4) the addition of an adjuvant was not shown
to increase the efficiency of the vaccine based on this testing method. Figure 4.5 and 4.6
represent the 200 g and 200 g+ adjuvant experimental groups, respectively. In both
experimental groups the spikes in antibody titer do not follow the curve typically seen in
response to a vaccine and in addition to the fact that all antibody concentrations return to
baseline following the spike in antibody concentrations indicated that the increase in antibody
titer was not due to the vaccine. The analyses (Tables 4.5 and 4.6) showed that there was no
significant antibody response from either group throughout the experiment. It also indicated that
the addition of an adjuvant did not increase the efficiency of the vaccine based on these testing
methods. It was demonstrated that throughout the course of the year-long experiment the average
antibody response was 0.1 antibody units (Figure 4.7) demonstrating that no antibody response
was able to be readily detected via this testing method.
4.4. Discussion
Throughout the yearlong study, 8 wethers died/ were euthanized for various reasons
(Table 4.7). None of the deaths were related to the vaccine and this was shown through
necropsies performed at the LSU Vet School. Two deaths were due to a Caseous Lymphadenitis
(CL) infection. CL is a chronic and highly contagious disease caused by the bacterium
Corynebacterium pseudotuberculosis. C. pseudotuberculosis is a gram positive, facultative,
intracellular coccobacillus which is found worldwide and is a major concern for small ruminants.
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Figure 4.1. The standard curve was analyzed using nonlinear regression and shows the absorbance rate at different concentrations of
RB51 antibodies present in cow sera vaccinated against RB51.
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Figure 4.2. Mean concentration of antibodies in samples obtained approximately every 6 weeks in wethers treated with sterile DBPS.
With an average adjusted P value of p=0.89 there was no difference between the samples taken prior to treatment (pre bleed) and the
subsequent samples, which was expected.
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Table 4.2. Serum Sample Comparison of Wethers Injected with DPBS between Pre-Injections Samples and Post-Injection Samples
Dunnett's multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 6 weeks

-0.7272 to 0.4305

0.8085

Pre-Bleed vs. 12 weeks

-0.5909 to 0.3865

0.9009

Pre-Bleed vs. 18 weeks

-0.4711 to 0.3834

0.9960

Pre-Bleed vs. 24 weeks

-0.5148 to 0.4192

0.9960

Pre-Bleed vs. 30 weeks

-0.7856 to 0.4478

0.7697

Pre-Bleed vs. 35 weeks

-0.7279 to 0.5426

0.9786

Pre-Bleed vs. 43 weeks

-0.8309 to 0.6070

0.9708

Pre-Bleed vs. 51 weeks

-3.380 to 1.779

0.6872
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Figure 4.3. Mean concentration of antibodies in samples obtained approximately every 6 weeks in wethers treated with a 1mL
subcutaneous injection of 100g of SDB3 rDNA vaccine. With an average adjusted P value of p=0.96 there was no difference
between the samples taken prior to treatment (pre bleed) and the subsequent samples.
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Table 4.3. Serum Samples Comparison of Wethers Injected with 100g of SDB3 between Pre-Injection Samples and Post-Injection
Samples
Dunnett's multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 6 weeks

-0.4664 to 0.7307

0.8804

Pre-Bleed vs. 12 weeks

-0.7701 to 0.8294

0.9998

Pre-Bleed vs. 18 weeks

-0.2439 to 0.3276

0.9783

Pre-Bleed vs. 24 weeks

-3.091 to 2.280

0.9747

Pre-Bleed vs. 30 weeks

-0.6733 to 0.9210

0.9711

Pre-Bleed vs. 35 weeks

-3.475 to 2.540

0.9711

Pre-Bleed vs. 43 weeks

-1.058 to 1.214

0.9996

Pre-Bleed vs. 51 weeks

-0.7917 to 1.182

0.9192
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Figure 4.4. Mean concentration of antibodies in samples obtained approximately every 6 weeks in wethers treated with a 1mL
subcutaneous injection of 100g of SDB3 rDNA vaccine and 200l of adjuvant. With an average adjusted P value of p=0.84 there
was no difference between the samples taken prior to treatment (pre bleed) and the subsequent samples.
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Table 4.4. Serum Sample Comparison of Wethers Injected with 100g of SDB3+ Adjuvant between Pre-Injection Samples and PostInjection Samples
Dunnett's multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 6 weeks

-0.6797 to 0.9506

0.9608

Pre-Bleed vs. 12 weeks

-0.7647 to 1.119

0.9341

Pre-Bleed vs. 18 weeks

-0.4737 to 0.8686

0.7238

Pre-Bleed vs. 24 weeks

-0.9474 to 1.531

0.8517

Pre-Bleed vs. 30 weeks

-0.9344 to 1.535

0.8359

Pre-Bleed vs. 35 weeks

-0.8901 to 1.525

0.7943

Pre-Bleed vs. 43 weeks

-0.8902 to 1.526

0.7936

Pre-Bleed vs. 51 weeks

-0.8961 to 1.532

0.7966
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Figure 4.5. Mean concentration of antibodies in samples obtained approximately every 6 weeks in wethers treated with a 1mL
subcutaneous injection of 200g of SDB3 rDNA vaccine. With an average adjusted P value of p=0.65 there was no difference
between the samples taken prior to treatment (pre bleed) and the subsequent samples.
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Table 4.5. Serum Sample Comparison of Wethers injected with 200g of SDB3 between Pre-Injection Samples and Post-Injection
Samples
Dunnett's multiple comparisons test

95.00% CI of diff.

Adjusted P Value

Pre-Bleed vs. 6 weeks

-0.8286 to 0.4526

0.7255

Pre-Bleed vs. 12 weeks

-0.08016 to 0.3040

0.2353

Pre-Bleed vs. 18 weeks

-0.7497 to 0.6262

0.9980

Pre-Bleed vs. 24 weeks

-0.09546 to 0.2829

0.3367

Pre-Bleed vs. 30 weeks

-0.9064 to 0.9673

0.9998

Pre-Bleed vs. 35 weeks

-0.3271 to 0.5677

0.7808

Pre-Bleed vs. 43 weeks

-2.054 to 1.506

0.9723

Pre-Bleed vs. 51 weeks

-0.08544 to 0.5321

0.1343
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Figure 4.6. Mean concentration of antibodies in samples obtained approximately every 6 weeks in wethers treated with a 1mL
subcutaneous injection of 200g of SDB3 rDNA vaccine and 200l of adjuvant. With an average adjusted P value of p=0.89 there
was no difference between the samples taken prior to treatment (pre bleed) and the subsequent samples.
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Table 4.6. Serum Sample Comparison of Wethers Injected with 200g of SDB3+Adjuvant between Pre-Injection Samples and PostInjection Samples
Dunnett's multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 6 weeks

-1.956 to 0.9699

0.6268

Pre-Bleed vs. 12 weeks

-0.6691 to 1.003

0.9167

Pre-Bleed vs. 18 weeks

-0.8423 to 0.5798

0.9386

Pre-Bleed vs. 24 weeks

-0.4214 to 0.5903

0.9599

Pre-Bleed vs. 30 weeks

-0.7592 to 0.9918

0.9867

Pre-Bleed vs. 35 weeks

-0.2716 to 0.4535

0.8202

Pre-Bleed vs. 43 weeks

-0.9316 to 1.429

0.8982

Pre-Bleed vs. 51 weeks

-0.6244 to 0.8932

0.9482
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Figure 4.7. The mean average of antibody concentration by week for the course of the experiment. The red line indicated the average
antibody concentration per week for all animals present for that bleed. The P value p=0.94 showed there was no difference between
the control and the treatment groups throughout the year long experiment.
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The disease is characterized by the formation of an abscess in or near the major peripheral lymph
nodes or within internal organs and lymph nodes. In the two cases that happened during this
experiment, the abscesses were discovered during a routine sample collection and were located
externally on the submandibular lymph node. Both animals were euthanized as soon as a
veterinary diagnosis was made to prevent the abscess from rupturing and infecting the other
animals. External abscesses are typically easy to diagnosis, but a definitive diagnosis can be
made by bacteriologic culture of purulent material from an intact abscess, which was the case in
this study. The animals were euthanized instead of being treated not only to reduce the risk of
exposing the entire herd but also because it is challenging if not impossible to eliminate this
bacterium from an individual animal (Washburn et al. 2019). Another disease that caused one of
the animals to be euthanized is Caprine Arthritis Encephalitis (CAE). CAE is a viral infection
that manifests in several different ways including polysynovitis-arthritis, indurative mastitis and
chronic wasting, however, most CAE infections are subclinical. The main form of spreading
CAE is through ingestion of virus infected colostrum or milk to kids. In adults the main form of
transmission is through horizontal transmission. This includes exposure to infected fomites,
ingestion of contaminated milk, or serial use of needles (Lofstedt 2014). Since the pathogenesis
of CAE is not fully understood, it was advised by a veterinarian that the animal be euthanized to
prevent the possibility of spreading the virus to the rest of the herd.
Upon analysis of the samples taken over the yearlong experiment it was shown that there
was no significant difference between the DBPS control group and the treatment groups (n=5). It
was also shown that there was no significant difference between the groups given an adjuvant in
conjunction with the rDNA vaccine and the groups that received the rDNA vaccine only.
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Within the DBPS control group one animal did have a spike in antibody titer at week 51,
which was possibly due to stress. In the experimental group that received a 100 g does of the
rDNA vaccine there were three animals that responded differently than the other two, which
showed no antibody response over the course of the experiment. Goat 1910 had a slight spike in
concentration at 18 weeks, however; it was not as high as the concentration at the time the prebleed sample was taken. Here, and throughout this document a slight spike will reference an
increase in antibody concentration measuring 0.5 antibody units and a major spike will measure
a raise in antibody concentration of 2 antibody units or more. Goat 1908 had a slight spike at 12
weeks and again at 35 and 43 weeks. Goat 1922 had the more major spikes in the group at week
24 and 35. Since animal 1910 had a slight spike that did not go above the pre-bleed
concentration, it can be considered error or due to stress and anemia. Goat 1908 did have several
small spikes. However, goat 1922 did have very major spikes compared to the other animals in
the experiment and it is unclear why. It is likely due to error in testing or an outside variable
because after the spikes the antibody titer returns to baseline level suggesting potential error.
When comparing the treatment group that received a 100 g does of the rDNA vaccine to the
group that received the 100 g injection+ a 200 l dose of an adjuvant, the group with the
adjuvant had no animals show any type of spike in antibody concentration. The five animals in
the 100 g injection+ adjuvant group showed little to no variation from the antibody
concentration detected at the time of the pre-bleed. With this information it was determined that
the addition of the adjuvant had no positive effect on the animals injected with a 100 g does of
the SDB3 vaccine.
In the treatment group that received a 200 g does of the rDNA vaccine there were two
animals that showed a spike in antibody concentration. Three of the goats showed little to no
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variation from the antibody concentration detected at the time of the pre-bleed. Goat 1917 had a
slight spike at week 6 and 30. Goat 1919, however, had a slight spike at weeks 6 and 18, but a
major spike at week 43. This major spike is similar in concentration to goat 1922 in the 100 g
vaccine group, but the spikes take place at varying weeks. It is possible that when the animal was
healthier it was able to mount an immune response to the vaccine, which would correlate to the
spike in antibody concentration. However, it could also suggest an error or an outside variable
effecting the samples. When comparing this treatment group and the 200 g injection + 200 l of
adjuvant treatment group, there was only one animal that showed a change in antibody
concentration. Four of the animals within the group had little to no variation of antibody
concentration between the pre-bleed and the following bleeds. Goat 1921 had a major spike at
weeks 6 and 18 and a slight spike at week 35. However, the reason the spike appears noteworthy
at 6 and 18 weeks was because between each spike the antibody concentration returns to baseline
and was in line with or lower than the antibody concentration detected at the time of the prebleed. It was unclear what caused the significant spikes in antibody concentration, but it does
suggest either error in testing or an external variable that influenced the animal or sample at
those times. Overall, through the testing and analysis of the sera samples over time it showed that
there was no significant difference between animals that received the DPBS control injection and
the animals that were injected with an rDNA vaccine. We concluded that the addition of the
adjuvant in this scenario did not influence the antibody concentration and if it did it was likely a
negative one seeing that the groups with the adjuvant had fewer animals that showed signs of a
spike in antibody concentration. This is because the protection awarded by vaccines depends not
only on the size of the vector, form of presentation or molecular complexity of the antigen but
also on the specific properties of the host immune system (Puentes et al. 1993). Antigens remain
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associated with follicular DC for months, therefore, a depot at this site may be more beneficial
for maintaining high antibody levels than a depot at the subcutaneous site (Allison and Byars
1986).
There are several possible reasons why the BabV3 epitopes were unable to be detected
through the ELISAs performed. The epitopes that were chosen for the BabV3 vaccine were
chosen from the literature because they have been shown in previous studies to be
immunodominant and elicit an immune response in an animal. However, in these studies the
entire epitope was utilized and for this project only portions of the epitopes were used. The
reduction in size of the epitopes may mean that the antigen coating the ELISAs is unable to
detect the portion of the epitopes chosen. Likewise, the primary antibody may also not be able to
readily detect the portions of the epitopes chosen. The vaccines were designed utilizing portions
of the epitopes opposed to the entire epitope in order to create an immune response to multiple
Brucella proteins known to be immunogenic. Acquiring antibodies specific to the epitopes from
the proteins utilized in the vaccines would have created a more specific ELSIA testing method
and potentially given more reliable results.
It has also been observed that IM injections opposed to subcutaneous injections may be
more beneficial in eliciting an immune response when utilizing pDNA. In a study performed on
mice, a single IM injection with as little as 10 g of plasmid was shown to significantly increase
the serum levels of the plasmid being detected (Tripathy et al. 1996). IM injections give the
opportunity for pDNA to be taken up by skeletal myocytes adjacent to the injection site and were
shown to be expressed for at least 19 months post injection in this study. The amount of pDNA
(10-100 g was tested) was directly proportional to the amount of plasmid production found at
the injection site. Thus, suggesting that IM injection of pDNA is a feasible option and potentially
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better than other injection methods. The increase of plasmid production was observed within 14
days post injection and remained elevated and stable over the course of the 90-day experiment.
To determine whether the pDNA remained at the injection site, the mice were sacrificed after the
90 days and varying tissues were collected. The elevated amount of plasmid was localized to the
injection site. However, these results may vary depending upon the transcriptional efficiency of
the vector (Tripathy et al. 1996) but based on the data shown pDNA should be able to be
reinjected after 90 days if dose elevation is required.
In another study utilizing IM injection of pDNA as an anti-tumor treatment in mice, it
was shown that the pDNA did not stay localized at the injection site. This was shown because in
other anti-tumor models an injection is given at the site of the tumor which can be impossible
when a tumor is located on internal organs. In this study by Horton et al. they showed that
through IM injection of pDNA in 3 different mouse tumor models a reduction in tumors was
seen despite not giving a localized injection or knowing where the tumor nodules were before
injection (Horton et al. 1999). IM injection allows for treatment of primary tumors at distant sites
and shows that pDNA when given via IM injection does have the ability to travel within the
body, but it was not determined how far or what the potential limitations are. It does suggest that
vaccinating an animal via IM injection would have the ability to be transported to immune cells
and not remain completely localized at the injection site.
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Table 4.7. Wethers Lost During Experimentation
Goat tag number
Experimental Vaccine Group
1914
Control
1918
200ug+ adjuvant

Cause of Death
Caseous Lymphadenitis (CL)
Borderline Caprine Arthritis
Encephalitis (CAE)

Date of Death/ Euthanasia
3/27/2020
5/11/2020

1913
1909
1905
1924
1910

200ug+ adjuvant
100ug+ adjuvant
200ug
100ug+ adjuvant
100ug

Pneumonia + parasites
Poor body condition/ anemia
Poor body condition/ anemia
CL
Asphyxiation

6/21/2020
7/1/2020
7/7/2020
8/25/2020
10/20/2020

1925

100ug+ adjuvant

Broken leg

3/3/2021
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Chapter 5. Vaccinating Pregnant Does with SDB3 to Determine Safety
Aim 1: To determine which dose of the vaccine shows the greater antibody response in does.
Aim 2: To determine if this rDNA vaccine is safe for pregnant animals and does not induce
abortion.
Aim 3: To determine whether the antibodies from the vaccine will be passed to the kid(s) via
colostrum.
5.1. Introduction
Vaccination during pregnancy provides many potential benefits. It’s an opportunity to
potentially prevent illnesses that effect pregnant women and fetal development. The possibility
of creating antibodies through safe vaccinations that could cross the placenta and provide
protection to a newborn soon after birth would be very beneficial (Vress 2021). Vaccination
during pregnancy allows for activation of both active and passive immunity. The mother receives
active immunity while allowing for passive immunity to be given to the newborn, protecting it
from infectious diseases after birth. Antibodies from the mother can also be transferred to the
newborn via colostrum and milk allowing the baby to remain protected until it develops active
immunity through vaccination as well (Arora et al. 2021). Pregnant individuals are one of the
most at risk groups when facing pathogens, however, due to little research involving pregnancy
and vaccinations this population of individuals remains at great risk. There are many
justifications for not vaccinating pregnant women including potential fetal death and
malformations (McMillan et al. 2015). Fetal harm and malformations are the main reasons why
women are not vaccinated during pregnancy; however, many studies show the risk for these
outcomes are low especially when vaccinated in the first trimester (McMillan et al. 2015).
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Live attenuated vaccines are not considered safe to be administered during pregnancy
because they may cause “fetal viremia/bacteremia.” Pregnancy causes the individual to be
immunocompromised, which increases the chances of catching certain diseases that the rest of
the population would be less effected by (Arora et al. 2021). However, inactivated vaccines are
generally considered to be safe which is why our lab tested a rDNA vaccine in pregnant animals.
This can further prove the safety of inactivated vaccines in pregnant individuals. The use of
rDNA vaccines potentially allows for the protection of the mother and fetus while also ensuring
that no harm comes to the fetus (Arora et al. 2021). There has been a more recent movement to
include pregnant women in vaccine studies to provide more effective means of protecting
pregnant women and animals and their offspring (Vress 2021).
5.2. Materials and Methods
5.2.1. Acquiring of and initial health check on does
Ten Boer goat does were acquired from and housed at Central Research Station
associated with LSU and were cared for in accordance with an approved IACUC protocol
number A2019-14. The animals were quarantined for 30 days before initiation of the experiment.
5.2.2 Experimental Set-Up
Ten does from the Central Research Station were used in this project. Typically, there is
one buck for every 20 does for optimal synchronized breeding, so the number of bucks needed
for breeding was determined by the number of does in the study (Extension 2009). They were
bred via natural service breeding by an untreated and unexposed buck also at the Central
Research Station. In south Louisiana, breeding typically occurs between August and October.
They were pastured together to breed on September 15 and gave birth in mid-February through
early March. This breeding schedule was done because the cold weather helps reduce the
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parasite population and reduces the risk of the doe or kid becoming infected. It was also done
because there should be no more extreme weather at this time of year, making it safer for the
newborn kids.
One group of experimental does was injected before breeding. The other group of does
being vaccinated were injected during pregnancy to show safety of the vaccine for a pregnant
animal while still showing effectiveness of the vaccine. Pregnancy checks were performed
starting at 21 days post breeding because goats cycle every 21 days and gestation typically lasts
151 days. The does vaccinated during pregnancy were injected around 90-110 days. Ideally, they
were vaccinated at day 100 when the uterus is most susceptible to a brucellosis infection. After
injection, three monitoring measures were taken.
Firstly, the experimental does were monitored for any noticeable ailments or death.
Second, the goats were monitored throughout gestation, and samples were collected at the time
of inoculation and every 6 weeks prior if it was safe for the pregnant does. Thirdly, the fetuses
were checked for viability. After parturition, the kids were tested within 24 hours of birth to
show whether the kids were able to obtain passive immunity against brucellosis through the
mother. It is thought that the rDNA vaccine will prove safe during pregnancy and the higher
vaccine dose will show the greatest antibody response.
5.2.3. Brucella Card Test
Blood samples were collected from the goats upon their arrival to determine a baseline
for their health. Thirty microliters of serum from each goat was placed at the lower half of the
“tear drop” on the Brucella Card Test. Each goat sample was placed in its own individual “tear
drop” for testing. Thirty microliters of the antigen that comes with the test was placed in each
tear drop, away from the sample. The antigen and serum sample were then mixed individually
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with a clean stirrer and the sample was spread throughout the tear drop shape. After each sample
was mixed, the entire card was gently rocked back and forth for 4 minutes which allows for the
mixture to flow into the apex so that the serum and antigen will be in proximity and then spread
out as it flows away allowing for proper mixing. Agglutination will occur if the sample is
positive. A positive control of serum from a Brucella infected cow was used and the negative
control was serum from a person known to be brucellosis free. All does tested negative on the
Brucella Card Test (Alton et al. 1988).
5.2.4. Experimental Groups
The does were randomly assigned to experimental groups. All the does injected with
the Brucella abortus vaccine 3 epitopes and the SXD backbone (SDB3) were also injected with
200l of adjuvant at the time of vaccination in a separate injection. All injections were done
subcutaneously on the right side of the neck. The information regarding the effect of the adjuvant
on the rDNA vaccine injected into wethers was not collected at this time.
5.2.5. Creation of the Vaccines for Injection
The 100 ug injections were created by adding the pDNA and 100 l of SuperFect
(Qiagen (Germantown, MD) into a microcentrifuge tube and mixing. An additional 200 l of
SuperFect was added in 100 l increments with mixing occurring between each 100 l addition.
The 300 g injections were created by adding pDNA into a microcentrifuge tube with 300 l
Superfect and mixed. Six hundred microliters of SuperFect was added in 300 l increments with
mixing by flicking happening after each addition for a total of 900 l of SuperFect in the 300 g
vaccine injection. The vaccines were prepared in this manner to prevent a precipitate from
forming between the DNA and the SuperFect.
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5.2.6. Processing Blood Samples
Samples were collected using a 20-gauge needle and a BD vacutainer blood collection
tube (BD, Franklin Lakes, NJ). The tubes were allowed to clot overnight in the 4°C and then
spun down in the centrifuge at 2200 x g for 20 minutes. The serum was then aliquoted and stored
in the -20°C freezer until needed for testing.
5.2.7. ELISA procedure
The 96 well EIA/RIA high binding plates (CoStar, Washington, D.C.) were coated with 5
g/mL of RB51 Brucella Antigen Stationary Phase and 1x carbonate buffer (pH 9.6) overnight at
4°C. Complete coating typically takes between 12-18 hours. The blocking buffer used was a 5%
bovine serum albumin (BSA) solution consisting of 40 g Sucrose+ 10 mL glycerol + 25 g BSA+
500 mL PBS. The primary and secondary antibodies were diluted in the 5%BSA blocking buffer
as well. A negative control consisting of 4 wells on the plate that did not receive primary
antibody but did receive secondary antibody was used. The positive control was sera from a cow
vaccinated with RB51 and it was set up in a 6-point serial dilution starting at a 1:50 dilution and
ending at 1:1600. Both vaccines were designed without the lipopolysaccharide (LPS) which is
present in the smooth strain of Brucella. This is similar to the live-attenuated vaccine, RB51,
which is also lacking LSP. The primary antibodies were the sample goat sera diluted with the
blocking buffer at a 1:1600 dilution. All samples were run in duplicates. There were two
secondary antibodies utilized on each ELISA and they were Rabbit anti Goat IgG (H+L) HRP
and Rabbit anti Bovine IgG (H+L) HRP. The bovine secondary antibody was used for the
positive control and two negative control wells. The goat secondary antibody was used for all
goat samples and two negative control wells. This was done to account for any background or
non-specific binding on the plate. The plate was washed between each step using the wash buffer
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consisting of 10XTBS and 20% tween 20. A reaction was visualized by the addition of 100 l of
1-Step Ultra TMB-ELISA buffer at room temperature and stopped at 2 minutes with 100 l 2M
H2SO4. The absorbance was measured on a Benchmark Plus Microplate Reader from Bio-Rad
(Hercules, CA) at 450 nm.
5.2.8. Data Analysis
The data was analyzed using a one-way analysis of variance (ANOVA) with repeated
measures and a post hoc Dunnett’s multiple comparisons test utilizing the program GraphPad
Prism 9. Values were normalized against sera taken from bovine vaccinated with RB51 to
accurately compare data between ELISA plates. The sera from bovine vaccinated with RB51 was
used as a six-point standard curve on each ELISA performed and was analyzed using nonlinear
regression (x=EC50((bottom-top)/Y-top)-1) ^(1/hillslope). Effects of the vaccine and adjuvant
on the animals were analyzed.
5.3. Results
The goats in the experiment were assigned experimental groups randomly (Table 5.1) and
the experiment was set up as a completely random design with repeated measures. A standard
curve (Figures 5.1 and 5.4) was utilized in ELISA testing, and it was analyzed using nonlinear
regression to demonstrate absorbance rate at different concentrations of RB51 antibodies present
in serum from a cow vaccinated against RB51. It was determined that P >0.1 signified that there
was no antibody response. An antibody response was determined to be P ≤ 0.05. Of the 2 groups
of treatment goats (100 g injection+ adjuvant and 300 g injection+ adjuvant) none of the
animals showed any antibody response over time. Figure 5.2 represents the 100 g+ adjuvant
experimental group in which two animals have a spike in antibody titer on the same week.
However, through analysis (Table 5.2) it was determined that there was no antibody titer able to
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be detected through the experiment for this group. Figure 5.3 depicts the 300 g+ adjuvant and
controls does and through analysis (Table 5.3) it was determined that no antibody titer was
detected throughout the experiment. In Figure 5.5 the antibody concentrations of the kids born
(Table 5.4) throughout the experiment were tested and it was shown that if they did receive
antibodies, it was able to be readily detected via this testing method.
5.4. Discussion
Upon analysis of the samples taken over the course of the experiment it was shown that
there was no significant difference between the does injected with sterile DBPB (n=2) and the
does injected with the SDB3 rDNA vaccine. Within the group injected with 100 g dose of the
vaccine+ adjuvant (n=5) there are two animals that had a spike in antibody concentration at 26
weeks. Goat 7213 had a major spike and goat 7210 had a slight spike and it was noted that it was
difficult to get a blood sample from these animals. Both does have no antibody response prior to
the spike and returned to baseline or pre-bleed antibody concentration in the weeks following the
spike in antibody concentration. It is unclear the exact reason for the increase in antibody
concentration, but it is possible that it was an error in testing or an environmental variable that
effected the sample such as stress when collecting the blood sample. The remaining 3 does in
this experimental group had little to no variation between the samples taken prior to injection and
post vaccination. In the experimental group injected with the 300 g dose of the vaccine+
adjuvant (n=3) none of the samples vary from the antibody concentration detected at the prebleed. Overall, this suggested that while the vaccine is safe to give to pregnant does in that it did
not induce abortion, the vaccine did not elicit an immune response.
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Table 5.1. Experimental Groups Containing Does
Goat ID Number
7213
7210
8206
8219
7211
8226
8203
7209
8222
8217

Experimental Group
100g injection + adjuvant
100g injection+ adjuvant
100g injection+ adjuvant
100g injection+ adjuvant
100g injection+ adjuvant
DPBS Control
DBPS Control
300g injection+ adjuvant
300g injection+ adjuvant
300g injection+ adjuvant

Figure 5.1. The standard curve was analyzed using nonlinear regression and shows the absorbance rate at different
concentrations of RB51 antibodies present in cow sera vaccinated against RB51.
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Figure 5.2. Mean concentration of antibodies in samples approximately every 6 weeks in does treated with 100g of SDB3 rDNA
vaccine + 200l of adjuvant. With an average adjusted P value of p=0.80 there was no difference between the samples taken prior to
treatment (pre-bleed) and the subsequent samples.
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Table 5.2. Serum Sample Comparison between Does Injected with 100g of SDB3+Adjuvant Between Pre-Injection Samples and
Post-Injection Samples
Dunnett's multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 6 weeks

-0.2322 to 0.2117

0.9997

Pre-Bleed vs. 12 weeks

-0.06542 to 0.1248

0.6722

Pre-Bleed vs. 17 weeks

-0.1137 to 0.2109

0.7015

Pre-Bleed vs. 26 weeks

-1.479 to 0.7144

0.5919

Pre-Bleed vs. 34 weeks

-0.1997 to 0.2392

0.9979

Pre-Bleed vs. 38 weeks

-0.09269 to 0.1717

0.7025

Pre-Bleed vs. 44 weeks

-0.1126 to 0.1566

0.9570
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Figure 5.3. Mean concentration of antibodies in samples approximately every 6 weeks in does treated with 100g of SDB3 rDNA
vaccine + 200l of adjuvant. With an average adjusted P value of p=0.95 there was no difference between the samples taken prior to
treatment (pre-bleed) and the subsequent samples.
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Table 5.3. Serum Sample Comparison of Does Injected with DBPS and 300g of SDB3+Adjuvant between Pre-Injection Samples and
Post-Injection Samples
Dunnett’s multiple comparisons test
95.00% CI of diff.
Adjusted P Value
Pre-Bleed vs. 4 weeks

-0.03632 to 0.05627

0.8234

Pre-Bleed vs. 12 weeks

-0.05559 to 0.04892

0.9966

Pre-Bleed vs. 16 weeks

-0.07020 to 0.06077

0.9947

Pre-Bleed vs. 22 weeks

-0.04736 to 0.05018

0.9998

Figure 5.4. The standard curve was analyzed using nonlinear regression and shows the absorbance rate at different concentrations of
RB51 antibodies present in cow sera vaccinated against RB51.
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Figure 5.5. Average antibody concentration of kids born during the safety experiment. All kids remained below 0.3 antibody units
suggesting there was no transfer of antibodies from mother to kid in the colostrum.
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Blood samples were taken from the kids within 24 hours post parturition to determine
whether the potential antibodies from the mother could be transferred to the kid via colostrum.
Because there was little to no antibody response in all the does, it was expected that the same
trend was observed in the kids.It has been shown in mice that when injected via IM with a pDNA
vaccine there is a possibility of passive protection from the mother to the progeny (Chang et al.
2000). One hundred percent of pups nursed from mothers with high antibody titers survived a
viral infection challenge. This study proves that it is achievable, but it does depend upon the
antibody response of the mother and based on this study, the amount of time the offspring is
given to nurse. Samples from the kids were taken within 24 hours after birth to look for passive
immunity from colostrum. However, the study performed by Chang and colleges showed that
older offspring from mothers with lower antibody concentrations were able to confer some
protection based upon how long they were able to nurse from the vaccinated mother (Chang et
al. 2000). This does suggest that the samples from the kids may have been taken too early to
accurately detect potential antibody concentration.
There are several possible reasons why the BabV3 epitopes were unable to be detected
through the ELISAs performed. The epitopes that were chosen for the BabV3 vaccine were
chosen from the literature because they have been shown in previous studies to be
immunodominant and elicit an immune response in an animal. However, in these studies the
entire epitope was utilized and for this project only portions of the epitopes were used. The
reduction in size of the epitopes may mean that the antigen coating the ELISAs is unable to
detect the portion of the epitopes chosen. Likewise, the primary antibody may also not be able to
readily detect the portions of the epitopes chosen. The vaccines were designed utilizing portions
of the epitopes opposed to the entire epitope in order to create an immune response to multiple
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Brucella proteins known to be immunogenic. Acquiring antibodies specific to the epitopes from
the proteins utilized in the vaccines would have created a more specific ELSIA testing method
and potentially given more reliable results.
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Table 5.4. Kids Born During Experiment
Date of birth
2/12/2021
2/16/2021
2/17/2021
2/19/2021

Doe Tag Number
7213
8206
8203
8226

Kid(s) Tag number
1201
1202
1203
1204

Doe Dose
100ug
100ug
DPBS Control
DPBS Control

2/20/2021
2/23/2021
3/1/2021
3/3/2021
3/5/2021
3/9/2021

8219
7209
7211
8222
7210
8217

1205 and 1206
1207 and 1208
1209 and 1210
1211
1212
1213 and 1214

100ug
300ug
100ug
300ug
100ug
300ug
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Notes

Male twin died within a day of birth
Male twin died within a day of birthtrouble nursing

Chapter 6. Conclusion
These experiments were designed to create a rDNA vaccine that could be successfully
transfected into cells and stimulate an immune response in animals. Throughout the course of
this project, it was proven that both the CPPB3 and SDB3 vectors were able to be successfully
transfected in vitro utilizing multiple cell lines and different methods of transfection. However,
these results were not able to be detected in an animal via an ELISA or through cell culture
ELISAs indicating that the ELISAs will need to be further optimized. The proteins that were
chosen to be utilized as epitopes in these vaccines were done so because they have already been
shown to be immunogenic in animals, however, in these experiments the entire protein sequence
was being utilized. For this project only epitopes were chosen to create a more complete immune
response. The difference in protein sequences may be one reason why the ELISAs were unable
to detect antibodies because the correct components for testing were not being used.
To improve upon this project 3 steps can be taken. The transfection reagent utilized for
the animal trials should be specific to in vivo testing to increase the number of transfected cells
thus increasing the potential antibody response and increasing the likelihood of detecting the
antibody concentration via an ELISA. Intramuscular injections can be utilized as well instead of
subcutaneous injections to increase the possibility of the pDNA being successfully transfected
into cells. Lastly, there needs to be antibodies created specific to the epitopes within these
vaccines. This can be done by creating an mRNA version of the SDB3 vaccine and vaccinating
another animal to create antibodies and retesting the samples. This will create specific antibodies
and potentially make the ELISA more specific, allowing determination of whether there was an
antibody response that was unable to be detected due to incorrect testing controls.
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